<html><head></head><body><h1>Interferon Alfa</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
- Biologic Response Modifiers<br/>
- Cytokines<br/>
<b>VA Class:</b> AM800<br/>
<b>Chemical Name:</b> Interferon α2b (human leukocyte clone Hif-SN206 protein moiety reduced)<br/>
<b>Molecular Formula:</b> C<sub>860</sub>H<sub>1353</sub>N<sub>229</sub>O<sub>255</sub>S<sub>9</sub>C<sub>860</sub>H<sub>1353</sub>N<sub>227</sub>O<sub>255</sub>S<sub>9</sub><br/>
<b>CAS Number:</b> 99210-65-8<br/>
<b>Brands:</b> Intron A, Alferon N</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>
<li>
<p>May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor patients closely with periodic clinical and laboratory evaluations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue therapy in patients with persistently severe or worsening signs or symptoms of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In many, but not all cases, these disorders resolve after the drug is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor patients closely with periodic clinical and laboratory evaluations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue therapy in patients with persistently severe or worsening signs or symptoms of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In many, but not all cases, these disorders resolve after the drug is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Interferon alfa is a family of proteins and glycoproteins with antiviral, antineoplastic, and immunomodulating activities.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;47&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;70&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;456&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;648&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;714&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;717&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;740&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;906&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1339&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1426&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1464&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Available in the US as interferon alfa-2b&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and interferon alfa-n3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also available covalently bound to monomethoxy polyethylene glycol (PEG) (i.e., peginterferon alfa).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;48&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;49&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Interferon Alfa</h2><h3>Chronic HBV Infection</h3><p>Interferon alfa-2b: Treatment of chronic HBV infection in adults, adolescents, and children ≥1 year of age with compensated liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Goal of antiviral therapy is sustained suppression of HBV replication and remission of liver disease;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; long-term goal is prevention of cirrhosis, hepatic failure, and hepatocellular carcinoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Currently available therapies (e.g., interferon alfa, peginterferon alfa, adefovir, entecavir, lamivudine, telbivudine, tenofovir) do not eradicate HBV and may have only limited long-term efficacy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When making decisions regarding treatment, consider patient’s age, severity of liver disease, likelihood of response, safety and efficacy of the drug, potential for selection of resistant HBV strains, potential for adverse reactions, costs, patient’s pregnancy potential, and patient and provider preferences.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>American Association for the Study of Liver Diseases (AASLD) states that drugs of choice for initial treatment of chronic HBV infection in patients with compensated liver disease are peginterferon alfa, entecavir, or tenofovir, unless contraindicated or ineffective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Efficacy of peginterferon alfa and nonconjugated interferon alfa are considered similar, but peginterferon alfa dosage schedule more convenient and generally preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of chronic HBV infection is complex and rapidly evolving and should be directed by clinicians familiar with the disease; consult specialist to obtain the most up-to-date information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Chronic HCV Infection</h3><p>Interferon alfa-2b: Has been used for treatment of chronic HCV infection in adults with compensated liver disease; used alone or in conjunction with oral ribavirin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b: Has been used for treatment of chronic HCV infection in treatment-naive children ≥3 years of age with compensated liver disease; used in conjunction with oral ribavirin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Peginterferon alfa (not interferon alfa) recommended if an interferon is used for treatment of chronic HCV infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interferon alfa alone or in conjunction with oral ribavirin associated with lower response rates than peginterferon alfa in conjunction with oral ribavirin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;36&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;37&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;38&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;39&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of chronic HCV infection is complex and rapidly evolving; consult a specialist to obtain the most up-to-date information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Information from the American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International Antiviral Society–USA (IAS–USA) regarding diagnosis and management of HCV infection, including recommendations for initial treatment, is available at [Web].&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Chronic HDV Infection</h3><p>Interferon alfa: Has been used with some limited success for treatment of chronic HDV infection† in adults and children coinfected with HBV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;99&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;130&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;141&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although interferon alfa may suppress viral activity in some patients, sustained response not obtained and relapse generally occurs after drug discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;141&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HDV infection only occurs in individuals with HBV infection since the virus depends on HBV for production of envelope proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Can be acquired as a coinfection with HBV or as a superinfection in HBV carriers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; HDV superinfection in HBV carriers almost always results in chronic infection with both viruses and is associated with high risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Human Papillomavirus (HPV) Infections</h3><p>Interferon alfa-2b, interferon alfa-n3: Intralesional treatment of external genital and perianal exophytic warts (condylomata acuminata) caused by HPV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>CDC states that intralesional interferon alfa is an alternative (not preferred) option for treatment of external HPV warts because of higher frequency of adverse effects (including rare severe systemic adverse effects) and/or less efficacy data compared with other options.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No currently available option has been shown to eradicate HPV infectivity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>West Nile Virus Infection</h3><p>Interferon alfa-2b, interferon alfa-n3: Have been investigated for treatment of serious West Nile virus (WNV) infection†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;93&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;94&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Despite initial case reports suggesting some clinical benefits in neuroinvasive disease,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;93&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;94&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; efficacy not proven in controlled clinical trials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;68&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Unlikely to inhibit WNV replication following establishment of infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;194&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Hairy Cell Leukemia</h3><p>Interferon alfa-2b: Treatment of hairy cell leukemia&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;439&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1620&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1621&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1623&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1627&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1629&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1635&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (leukemic reticuloendotheliosis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1636&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Complete response achieved in 10% of patients and overall response achieved in approximately 80% of patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;122&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;123&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;126&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;131&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;134&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;136&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;138&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;142&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;143&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;170&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;178&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;182&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;192&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;237&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;239&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;248&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;250&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;439&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1620&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1624&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1635&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1636&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>An alternative for hairy cell leukemia; cladribine or pentostatin preferred (achieve higher complete response rates than interferon alfa).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;439&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1619&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1620&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1621&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1622&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1623&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1624&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1627&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1632&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1637&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>AIDS-related Kaposi’s Sarcoma</h3><p>Interferon alfa-2b: Palliative treatment of AIDS-related Kaposi’s sarcoma in selected adults&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;152&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;206&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;210&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;378&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1647&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1648&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (designated an orphan drug by FDA for this indication).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1546&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use in patients with rapidly progressive visceral or life-threatening disease;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1549&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; response generally is slow&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;88&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;156&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1549&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and poor.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;154&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;155&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;156&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;203&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;378&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;381&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;383&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;384&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;385&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;387&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;389&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1549&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Likelihood of response to interferon alfa is greater in patients without systemic symptoms who have limited lymphadenopathy and relatively intact immune systems as indicated by CD4<sup>+</sup> T-cell counts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>All patients with AIDS-related Kaposi's sarcoma should be receiving highly active antiretroviral therapy; in some patients, initiation of antiretroviral therapy alone may result in tumor regression and resolution of lesions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Non-Hodgkin’s and Cutaneous T-cell Lymphomas</h3><p>Interferon alfa-2b: Although labeled by FDA for use in conjunction with an anthracycline for initial treatment of clinically aggressive follicular non-Hodgkin’s lymphoma in adults,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; other agents preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;442&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efficacy in patients with low-grade, low-tumor-burden follicular non-Hodgkin’s lymphoma not demonstrated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa: Has been used for treatment of cutaneous T-cell lymphomas†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;217&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;254&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;299&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;342&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1382&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1385&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Melanoma</h3><p>Interferon alfa-2b: Used as an adjunct to surgery (within 56 days of surgery) in adults with malignant melanoma who are disease free but at high risk for systemic recurrence.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Palliative treatment of metastatic melanoma† in selected patients, alone and in conjunction with other therapies (e.g., radiation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1342&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1343&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1345&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1347&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1443&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1444&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1445&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1446&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1530&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1531&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1532&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Basal Cell and Squamous Cell Skin Cancers</h3><p>Interferon alfa: Has been used intralesionally for treatment of basal cell carcinoma†&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;272&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1466&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1467&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1468&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1469&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1470&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and squamous cell carcinoma†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;158&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Chronic Myelogenous Leukemia</h3><p>Interferon alfa-2b: Has been used for treatment of adult-type (Philadelphia chromosome-positive) chronic myelogenous (myelocytic, myeloid) leukemia (CML)†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;299&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;300&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;301&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;307&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;308&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;310&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;311&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;312&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;441&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1029&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1420&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1479&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1533&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1594&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1638&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1639&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1640&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1641&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1642&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1643&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1644&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Renal Cell Carcinoma</h3><p>Interferon alfa: Has been used for treatment of metastatic renal cell carcinoma† in selected patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;443&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;715&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1625&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1694&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1697&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Bladder Cancer</h3><p>Interferon alfa: Has been used intravesically† for prophylaxis&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;351&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or treatment&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;356&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;448&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1552&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; of superficial bladder cancer†.</p><h3>Ovarian Cancer</h3><p>Interferon alfa: Has been used intraperitoneally for treatment of minimal residual epithelial ovarian cancer† in a limited number of patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;359&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;360&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Interferon Alfa Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Various interferon alfa subtypes (alfa-2b, n3) and dosage forms (powder for injection, solution for injection) are commercially available;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; preparation to be used and appropriate concentration depend on intended use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Ensure that correct preparation is used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Various interferon alfa subtypes (alfa-2b, n3) and dosage forms (powder for injection, solution for injection) are commercially available;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; preparation to be used and appropriate concentration depend on intended use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Ensure that correct preparation is used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Interferon alfa-2b (Intron<sup></sup> A): Administer by IM, sub-Q, or intralesional injection or by IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3 (Alferon<sup></sup> N): Administer by intralesional injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b may be <i>self-administered</i> if clinician determines that the patient and/or their caregiver are competent to prepare and safely administer the drug after appropriate training and with medical follow-up as necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administration in the evening or at bedtime may prevent or ameliorate some adverse effects (e.g., flu-like syndrome).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administration of acetaminophen or other nonopiate analgesic at the time interferon alfa dose is given may reduce incidence of adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use single-dose vial of interferon alfa-2b powder for injection containing 10, 18, or 50 million units to prepare IV solutions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use solution for injection available in multiple-dose vials for IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Melanoma (induction therapy): Reconstitute single-dose vial of powder for injection containing 10, 18, or 50 million units by adding 1 mL of sterile water for injection provided by manufacturer; resultant solution contains 10, 18, or 50 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Withdraw appropriate dose of reconstituted solution and add to 100 mL of 0.9% sodium chloride injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not dilute to final concentration &lt;10 million units/100 mL (&lt;100,000 units/mL).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prepare IV solutions immediately before use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by IV infusion over 20 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Depending on indication and dosage, use single-dose vial of powder for injection or multiple-dose vial of solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When powder for injection is indicated for IM injection, reconstitute single-dose vial of powder for injection containing 10 or 50 million units by adding 1 mL of sterile water for injection provided by manufacturer; resultant solution contains 10 or 50 million units/mL, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Withdraw appropriate dose and administer IM undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When multiple-dose vial containing 6 or 10 million units/mL is indicated for IM injection, withdraw appropriate dose and administer IM undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer IM into anterolateral thigh, upper arm, or outer area of the buttocks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chronic HBV infection: Use single-dose vial of powder for injection containing 10 million units or multiple-dose vial containing 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chronic HCV infection: Use multiple-dose vial containing 6 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hairy cell leukemia: Use single-dose vial of powder for injection containing 10 million units or multiple-dose vial containing 6 or 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use IM injection if platelet count &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>AIDS-related Kaposi's sarcoma: Use single-dose vial of powder for injection containing 50 million units.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Depending on indication and dosage, use single-dose vial of powder for injection or multiple-dose vial of solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When powder for injection is indicated for sub-Q injection, reconstitute single-dose vial of powder for injection containing 10, 18, or 50 million units by adding 1 mL of sterile water for injection provided by manufacturer; resultant solution contains 10, 18, or 50 million units/mL, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Withdraw appropriate dose and administer sub-Q undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When multiple-dose vial containing 6 or 10 million units/mL is indicated for sub-Q injection, withdraw appropriate dose and administer sub-Q undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer sub-Q into anterolateral thigh, upper arm, or abdomen (avoiding navel).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not make sub-Q injections into areas where skin is irritated, red, bruised, infected, or has scars, stretch marks, or lumps.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chronic HBV infection: Use single-dose vial of powder for injection containing 10 million units or multiple-dose vial containing 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chronic HCV infection: Use multiple-dose vial containing 6 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hairy cell leukemia: Use single-dose vial of powder for injection containing 10 million units or multiple-dose vial containing 6 or 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>AIDS-related Kaposi's sarcoma: Use single-dose vial of powder for injection containing 50 million units.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use multiple-dose vials containing solution for injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Follicular non-Hodgkin's lymphoma: Use single-dose vial of powder for injection containing 10 million units or multiple-dose vial containing 6 or 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Melanoma (maintenance therapy): Use single-dose vial of powder for injection containing 10 or 18 million units or multiple-dose vial containing 6 or 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of external genital and perianal warts (condylomata acuminata): Reconstitute single-dose vial of powder for injection containing 10 million units by adding 1 mL of sterile water for injection diluent provided by manufacturer; resultant solution contains 10 million units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Withdraw appropriate dose and administer intralesionally undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternatively, withdraw appropriate dose of solution for injection from multiple-dose vial containing 25 million units/mL and administer intralesionally undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use a tuberculin or similar syringe and a 25- to 30-gauge short (e.g., 0.25- to 0.5-inch) needle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Direct needle toward center of base of wart, at an angle nearly parallel to the plane of the skin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maintain needle at this angle to deliver the drug to dermal core of the lesion, infiltrating lesion and causing formation of a small wheal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use single-dose vials of powder for injection containing 18 or 50 million units or multiple-dose vials containing 6 million units/mL to prepare solutions for intralesional injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of external genital and perianal warts (condylomata acuminata): Administer intralesionally undiluted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use a 30-gauge needle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Direct needle toward base of wart.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Because of differences in potencies and recommended dosages and routes of administration among the various commercially available interferon alfa preparations, use the interferon alfa preparation selected for the patient throughout the treatment regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Caution patients not to change brands or alter dosage without consulting clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥1 year of age: 3 million units/m<sup>2</sup> 3 times weekly for first week, then 6 million units/m<sup>2</sup> 3 times weekly (maximum of 10 million units 3 times weekly).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer recommends treatment duration of 16–24 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; AASLD recommends 16–24 weeks in hepatitis B e antigen (HBeAg) -positive patients and ≥12 months in HBeAg-negative patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Duration of 24 months may increase rate of sustained response in HBeAg-negative patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: Reduce dosage by 50% if leukocyte count &lt;1500/mm<sup>3</sup>, granulocyte count &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If leukocyte, granulocyte, and/or platelet counts return to normal or baseline values, resume at up to 100% of initial dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if leukocyte count &lt;1000/mm<sup>3</sup>, granulocyte count &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥3 years of age (treatment-naive): 3 million units 3 times weekly in conjunction with oral ribavirin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer of interferon alfa-2b recommends 18–24 months of concomitant therapy if well tolerated and serum ALT concentrations are normalized at 16 weeks; if ALT concentrations have not normalized or if high plasma HCV RNA levels persist after 16 weeks of treatment, consider discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturers of oral ribavirin recommend 24–48 weeks of concomitant therapy; consider discontinuance if plasma HCV RNA levels not below limits of detection at 24 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification of interferon alfa-2b for toxicity: Reduce dosage by 50%;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; discontinue if reduced dosage not tolerated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reduce dosage if leukocyte count 1000 to &lt;1500/mm<sup>3</sup>, neutrophil count 500 to &lt;750/mm<sup>3</sup>, or platelet count 50,000 to &lt;70,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if leukocyte count &lt;1000/mm<sup>3</sup>, neutrophil count &lt;500/mm<sup>3</sup>, platelet count &lt;50,000/mm<sup>3</sup>, hemoglobin &lt;8.5 g/dL, or S<sub>cr</sub> &gt;2 mg/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If severe depression and/or suicidal ideation occurs, discontinue and initiate appropriate psychiatric care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>30–35 million units per week (given as 5 million units once daily or 10 million units 3 times weekly).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer recommends treatment duration of 16 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; AASLD recommends 16–24 weeks in HBeAg-positive patients and ≥12 months in HBeAg-negative patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Duration of 24 months may increase rate of sustained response in HBeAg-negative patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;97&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: Reduce dosage by 50% if leukocyte count &lt;1500/mm<sup>3</sup>, granulocyte count &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If leukocyte, granulocyte, and/or platelet counts return to normal or baseline values, resume at up to 100% of initial dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if leukocyte count &lt;1000/mm<sup>3</sup>, granulocyte count &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3 million units 3 times weekly in conjunction with oral ribavirin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer of interferon alfa-2b recommends 18–24 months of concomitant therapy if well tolerated and serum ALT concentrations are normalized at 16 weeks; if ALT concentrations have not normalized or if high plasma HCV RNA levels persist after 16 weeks of treatment, consider discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturers of oral ribavirin recommend 24–48 weeks of concomitant therapy; consider discontinuance if plasma HCV RNA levels not below limits of detection at 24 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification of interferon alfa-2b for toxicity: Reduce dosage by 50%;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; discontinue if reduced dosage not tolerated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reduce dosage if leukocyte count 1000 to &lt;1500/mm<sup>3</sup>, neutrophil count 500 to &lt;750/mm<sup>3</sup>, or platelet count 25,000 to &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if leukocyte count &lt;1000/mm<sup>3</sup>, neutrophil count &lt;500/mm<sup>3</sup>, platelet count &lt;25,000/mm<sup>3</sup>, or hemoglobin concentration &lt;8.5 g/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If severe depression and/or suicidal ideation occurs, decrease dosage and initiate appropriate psychiatric care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3 million units 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer recommends treatment duration of 18–24 months if well tolerated and serum ALT concentrations are normalized at 16 weeks; if ALT concentrations have not normalized or if high plasma HCV RNA levels persist at 16 weeks, consider discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: If severe adverse effects develop, reduce dosage by 50% or temporarily interrupt therapy until adverse events resolve.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue if intolerance persists after dosage adjustment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>1 million units into each lesion (up to 5 lesions) 3 times weekly on alternate days for 3 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Another course may be administered after 12–16 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>250,000 units (0.05 mL) into each wart twice weekly for up to 8 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Large warts may be injected at multiple locations around their periphery, using a total dose of 250,000 units per lesion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maximum dose per treatment session is 2.5 million units.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: Regimen may need to be modified or discontinued if moderate to severe adverse effects occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Delay administration of a second course or other therapy until 3 months after first course unless warts enlarge or new lesions develop; many patients do not exhibit complete resolution of lesions until 3 months following cessation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of a second course not determined.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>2 million units/m<sup>2</sup> 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;126&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;131&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;179&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1152&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Administer sub-Q (not IM) if platelet count &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimum treatment duration not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;141&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1549&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturer states continue for up to 6 months;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; patients not responding may benefit from continued treatment, but discontinue if disease progresses or fails to respond after 6 months of treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If no evidence of disease progression, some clinicians suggest continuing for at least 12 months before considering discontinuance for nonresponse.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;141&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;250&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1549&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: If severe adverse effects develop, reduce dosage by 50% or temporarily interrupt therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If adverse effects abate, resume using reduced dosage (1 million units/m<sup>2</sup> 3 times weekly).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if severe adverse effects persist or recur after dosage reduction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>FDA-labeled dosage is 30 million units/m<sup>2</sup> 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Response is slow; maximum effect occurs after ≥6 months of treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continue until disease progresses or maximal response is achieved after 16 weeks of treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: If severe adverse effects develop, reduce dosage by 50% or temporarily interrupt therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If adverse effects abate, may resume using reduced dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if severe adverse effects persist or recur after dosage reduction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>5 million units 3 times weekly in conjunction with anthracycline-containing chemotherapy regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continue interferon alfa-2b after completion of chemotherapy regimen;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; interferon alfa-2b is given for up to 18 months.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Doses of myelosuppressive drugs were reduced by 25% from full dose and cycle length increased by 33% (e.g., from 21 to 28 days) when interferon alfa was added to the regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Delay chemotherapy cycle if neutrophil counts &lt;1500/mm<sup>3</sup> or platelet counts &lt;75,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification of interferon alfa-2b for toxicity: Withhold if neutrophil count &lt;1000/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reduce dosage by 50% (2.5 million units 3 times weekly) if neutrophil count &gt;1000/mm<sup>3</sup> but less than 1500/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May reescalate to initial starting dosage (5 million units 3 times weekly) if hematologic toxicity resolves (ANC &gt;1500/mm<sup>3</sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if AST &gt;5 times ULN or S<sub>cr</sub> &gt;2 mg/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Induction therapy: 20 million units/m<sup>2</sup> daily for 5 consecutive days per week for 4 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: Withhold for severe adverse effects (e.g., granulocyte count &gt;250/mm<sup>3</sup> but &lt;500/mm<sup>3</sup>, ALT and/or AST &gt;5 to 10 times ULN).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When adverse effects abate, may reinitiate at 50% of previous dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if toxicity does not abate while drug withheld, serious adverse effects recur after reduced dosage, granulocyte count &lt;250/mm<sup>3</sup>, or ALT and/or AST &gt;10 times ULN.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maintenance therapy: 10 million units/m<sup>2</sup> 3 times weekly for 48 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification for toxicity: Withhold for severe adverse effects (e.g., granulocyte count &gt;250/mm<sup>3</sup> but &lt;500/mm<sup>3</sup>, ALT and/or AST &gt;5 to 10 times ULN).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When adverse effects abate, may reinitiate at 50% of previous dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanently discontinue if toxicity does not abate while drug withheld, serious adverse effects recur after reduced dosage, granulocyte count &lt;250/mm<sup>3</sup>, or ALT and/or AST &gt;10 times ULN.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum dosage is 10 million units 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum 5 warts treated per course (total dose 5 million units).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum recommended dose per treatment session is 2.5 million units.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Concomitant interferon alfa-2b (Intron<sup></sup> A) and oral ribavirin therapy contraindicated in patients with Cl<sub>cr</sub> &lt;50 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Interferon Alfa</h2><h3>Contraindications</h3><ul>
<li>
<p>Interferon alfa-2a (Intron<sup></sup> A): Known hypersensitivity (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) to interferon alfa or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Interferon alfa-n3 (Alferon<sup></sup> N): Known hypersensitivity to human interferon alfa proteins or any component in the formulation; history of anaphylactic reactions to murine (mouse) IgG, egg protein, or neomycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Sensitivity Reactions under Cautions.)</p>
</li>
<li>
<p>Interferon alfa-2b: Autoimmune hepatitis&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or hepatic decompensation (Child-Pugh score &gt;6, class B and C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>(See Hepatic Effects under Cautions.)</i></p>
</li>
<li>
<p>Interferon alfa-2b: Concomitant use of oral ribavirin contraindicated in women who are or may become pregnant, men whose female partners are pregnant, patients with known hypersensitivity to ribavirin or any ingredient in the formulation, patients with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia), and patients with Cl<sub>cr</sub> &lt;50 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Interferon alfa-2a (Intron<sup></sup> A): Known hypersensitivity (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) to interferon alfa or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3 (Alferon<sup></sup> N): Known hypersensitivity to human interferon alfa proteins or any component in the formulation; history of anaphylactic reactions to murine (mouse) IgG, egg protein, or neomycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Sensitivity Reactions under Cautions.)</p><p>Interferon alfa-2b: Autoimmune hepatitis&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or hepatic decompensation (Child-Pugh score &gt;6, class B and C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>(See Hepatic Effects under Cautions.)</i></p><p>Interferon alfa-2b: Concomitant use of oral ribavirin contraindicated in women who are or may become pregnant, men whose female partners are pregnant, patients with known hypersensitivity to ribavirin or any ingredient in the formulation, patients with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia), and patients with Cl<sub>cr</sub> &lt;50 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor closely with periodic clinical and laboratory evaluations; discontinue in those with persistently severe or worsening signs or symptoms of these disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In many, but not all cases, these disorders resolve after interferon alfa discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Other Warnings/Precautions under Cautions.)</p><p>Observe usual cautions, precautions, and contraindications associated with oral ribavirin when the drug is used concomitantly with interferon alfa-2b for treatment of chronic HCV infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ribavirin may cause birth defects and/or fetal death.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If oral ribavirin used in conjunction with interferon alfa, extreme care must be taken to avoid pregnancy in female patients and female partners of male patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pregnancy under Cautions.)</p><p>Ribavirin causes hemolytic anemia, which may exacerbate cardiac disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serious, acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) reported rarely in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If serious hypersensitivity reaction occurs, immediately discontinue interferon alfa and provide appropriate supportive care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Transient rash reported; has not necessitated interruption of interferon alfa treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3: May contain trace amounts of murine (mouse) protein which can stimulate antibody formation in some patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although egg protein (ovalbumin) not detected in final product, manufacturing process includes propagation in chick embryo tissue culture and possibility exists that patients receiving the drug could develop hypersensitivity to egg protein.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Contraindications under Cautions.)</p><p>Depression, psychoses, suicidal ideation or suicidal attempts (including some fatalities), hallucinations, aggressive or violent behavior, and rare cases of homicidal ideation reported with interferon alfa (alone or in conjunction with oral ribavirin) in patients with and without preexisting psychiatric disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Exacerbated symptoms of psychiatric disorders may occur in patients with both psychiatric and substance use disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If initiated in patient with history of psychiatric conditions or substance use disorders, consider need for drug screening and periodic clinical evaluation, including psychiatric symptom monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Early intervention for new or re-emergent neuropsychiatric symptoms or substance use recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Obtundation, coma, and encephalopathy reported, primarily in geriatric patients treated with high interferon alfa dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with history of preexisting psychiatric disorders, especially those with history of depression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Closely monitor all patients for evidence of depression and other psychiatric symptoms and advise patients to immediately report any sign or symptom of depression or suicidal ideation to their clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If severe depression and/or other psychiatric condition develops, immediately discontinue interferon alfa and provide appropriate psychiatric intervention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hypotension,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;148&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;206&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;208&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;470&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; arrhythmia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;300&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;374&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;461&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;465&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;469&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;470&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;475&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; tachycardia (≥150 bpm),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; cardiomyopathy,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;155&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;469&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;470&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1340&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1362&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and MI&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;235&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;341&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;461&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;465&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;470&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;471&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;473&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;474&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;490&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;963&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; reported in patients with or without history of cardiovascular disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hypotension may occur during administration or up to 2 days posttherapy and may require supportive therapy, including fluid replacement to maintain intravascular volume.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Supraventricular arrhythmias have occurred rarely and appeared to correlate with preexisting cardiovascular conditions and prior therapy with cardiotoxic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These adverse experiences were controlled by modifying dosage or discontinuing the drug, but may require additional specialized care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform ECG prior to and periodically during interferon alfa therapy in patients with preexisting cardiac abnormalities and/or advanced stages of cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution and close monitoring in those with cardiovascular disease or history of any cardiac condition, including MI or arrhythmia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use concomitant interferon alfa and oral ribavirin in patients with history of substantial or unstable cardiac disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ischemic and hemorrhagic cerebrovascular events, including hemorrhagic stroke, reported in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Such events have occurred in patients with few or no risk factors for stroke, including patients &lt;45 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Causal relationship not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Suppresses bone marrow function and may cause severe cytopenias and anemia, including aplastic anemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use in patients with hemoglobinopathies (e.g., thalassemia, sickle cell anemia).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform CBCs prior to and routinely during interferon alfa therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust dosage or discontinue drug if necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Because mild to moderate leukopenia has been reported in patients receiving intralesional interferon alfa, also consider hematologic monitoring in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with coagulation disorders (e.g., pulmonary embolism, thrombophlebitis, hemophilia).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also use with caution in patients with myelosuppression or receiving drugs that may be myelosuppressive (e.g., zidovudine).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Specific Drugs under Interactions.)</p><p>Most frequent adverse effect of interferon alfa is flu-like syndrome,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; generally characterized by fever,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; headache,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; chills,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; myalgia/arthralgia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; fatigue,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; increased sweating,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; asthenia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rigors,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; dizziness,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; influenza-like symptoms,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; back pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; dry mouth,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; chest pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; malaise,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and pain (unspecified).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consider other possible causes if persistent high fever occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with debilitating diseases such as cardiac disease (e.g., unstable angina, uncontrolled CHF), severe pulmonary disease (e.g., COPD), or diabetes mellitus (prone to ketoacidosis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decrease or loss of vision and retinopathy, including macular edema, optic neuritis, papilledema, retinal hemorrhages, cotton-wool spots, serous retinal detachment, and retinal artery or vein thrombosis, may be induced or aggravated by interferon alfa therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform baseline ophthalmologic examinations in all patients prior to initiation of interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Perform ophthalmologic examinations periodically during interferon alfa therapy in those with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform prompt and complete eye examination in any patient who develops ocular symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue in patients who develop new or worsening ophthalmologic disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause or aggravate thyroid dysfunction (hypothyroidism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;507&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;508&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;510&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1361&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1533&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1565&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or hyperthyroidism).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;507&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;509&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;510&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1361&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1362&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1533&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1565&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Evaluate TSH prior to initiation of interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If symptoms consistent with possible thyroid dysfunction occur during interferon alfa therapy, evaluate thyroid function and initiate treatment if needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa can be continued in patients with hypothyroidism or hyperthyroidism if thyroid function can be normalized with antithyroid therapy or hormone replacement therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Development of diabetes mellitus and hyperglycemia reported rarely in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interferon alfa can be continued in patients with diabetes mellitus as long as their diabetes can be controlled with drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with chronic HBV infection may experience transient increase (&gt;2 times baseline) in serum ALT (“flare”), usually 8–12 weeks following initiation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interferon alfa generally can be continued, unless there are signs and symptoms of liver failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor symptomatology, liver function tests (serum ALT, alkaline phosphatase, albumin, bilirubin), and PT at approximately 2-week intervals during these occurrences.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Patients with chronic HBV infection and evidence of decreasing hepatic synthetic function (e.g., decreasing serum albumin, prolonged PT) may be at increased risk of clinical decompensation if an increase in serum ALT occurs during interferon alfa therapy; use the drug with caution and close monitoring of symptoms and liver function tests if serum ALT increases.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Closely monitor patients who develop liver function abnormalities (e.g., increase in serum ALT) during interferon alfa therapy and discontinue the drug as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Worsening liver disease, including jaundice, hepatic encephalopathy, hepatic failure, and death, reported in patients with decompensated liver disease, autoimmune hepatitis, history of autoimmune disease, or immunosuppression (e.g., organ transplant recipients) treated with interferon alfa; do not use the drug in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately discontinue if manifestations of hepatic decompensation (e.g., jaundice, ascites, coagulopathy, decreased serum albumin concentrations) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated in patients with hepatic decompensation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Contraindications under Cautions.)</p><p>Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis reported; respiratory failure and/or death has occurred,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; principally in those receiving the drug for treatment of chronic HCV infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Etiologic explanation for these findings not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>One manufacturer suggests baseline chest radiographs in all patients before initiating interferon alfa and whenever clinically indicated in patients who develop fever, cough, dyspnea, or other respiratory symptoms during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recurrence of respiratory failure has occurred with interferon rechallenge; closely monitor patients if interferon alfa resumed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Development or exacerbation of autoimmune disease (e.g., autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, vasculitis, Raynaud’s phenomenon, rheumatoid arthritis, psoriasis, interstitial nephritis, thyroiditis, lupus erythematosus, hepatitis, rhabdomyolysis) reported in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fatalities reported rarely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If autoimmune disease develops, closely monitor and discontinue the drug if necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b contains albumin (a derivative of human blood);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; interferon alfa-n3 is produced using human leukocytes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Because of effective donor screening and product manufacturing processes, these preparations are associated with an extremely remote risk for transmission of viral diseases and a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pancreatitis (sometimes fatal) reported in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Suspend interferon alfa in patients with signs and symptoms of pancreatitis (e.g., abdominal pain, nausea, vomiting); discontinue the drug if a diagnosis of pancreatitis is established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Peripheral neuropathy reported in patients receiving telbivudine concomitantly with an interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Specific Drugs under Interactions.)</p><p>Increased serum triglycerides reported in patients receiving interferon alfa alone or in conjunction with oral ribavirin; severe hypertriglyceridemia may result in pancreatitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pancreatitis under Cautions.)</p><p>Consider discontinuing interferon alfa in patients with persistently elevated triglycerides (&gt;1000 mg/dL) accompanied by symptoms suggestive of pancreatitis (abdominal pain, nausea, vomiting).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dental and periodontal disorders reported in patients receiving interferon alfa and oral ribavirin;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; dry mouth may contribute to damage of teeth and oral mucous membranes during long-term treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients to have regular dental examinations during treatment, brush their teeth thoroughly twice daily, and rinse their mouth thoroughly after vomiting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serum anti-interferon neutralizing antibodies may develop in patients receiving interferon alfa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No apparent correlation of antibody development to clinical response or adverse events.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of interferon alfa alone or in conjunction with oral ribavirin not established for treatment of chronic HCV infection in patients with liver or other transplants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa (alfa-2b, alfa-n3) monotherapy: Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant interferon alfa (alfa-2b) and oral ribavirin: Category X.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether interferon alfa is distributed into milk;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; murine interferons distribute into milk in mice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing or the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b: Safety and efficacy established for treatment of chronic HBV infection in children 1–17 years of age and for treatment of chronic HCV infection in treatment-naive children 3–16 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Safety and efficacy not established for any other indications in pediatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3: Safety and efficacy not established in children &lt;18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Suicidal ideation or attempted suicide reported more frequently in pediatric patients (principally adolescents) receiving interferon alfa than in adults receiving the drug; these events occurred during treatment and following discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Delay in weight and height increases compared with baseline reported in pediatric patients receiving interferon alfa for treatment of chronic HBV or HCV infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;52&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with chronic HBV infection may be at risk for transient acute exacerbations (flares) of HBV infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>(See Hepatic Effects under Cautions.)</i></p><p>Closely monitor clinical status and hepatic function; immediately discontinue interferon alfa if decompensation occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>(See Hepatic Effects under Cautions.)</i></p><p>Interferon alfa-2b: Contraindicated in patients with autoimmune hepatitis or hepatic decompensation (Child-Pugh score &gt;6, class B and C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant interferon alfa-2b and oral ribavirin contraindicated if Cl<sub>cr</sub> &lt;50 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Flu-like symptoms (e.g., fever, headache, chills, myalgia/arthralgia, fatigue, increased sweating, asthenia, rigors, dizziness),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; abdominal pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; alopecia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; anemia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; anorexia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; back pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; depression,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; diarrhea,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; dyspnea,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; musculoskeletal pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; nausea,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; neutropenia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; pharyngitis,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; somnolence,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; vomiting,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; weight loss.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Interferon Alfa</h2><h3>Drugs Metabolized by Hepatic Microsomal System</h3><p>Interferons may inhibit hepatic CYP enzyme system.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;44&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;950&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;951&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;952&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;953&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;954&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1544&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Aldesleukin</p><p>Hypersensitivity reactions, development or exacerbation of autoimmune disease and inflammatory disorders, and increased incidence of myocardial injury (e.g., MI, myocarditis, ventricular hypokinesia, severe rhabdomyolysis) reported&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1747&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antineoplastic agents</p><p>Additive or synergistic antineoplastic activity with certain cytotoxic agents (e.g., cisplatin, cyclophosphamide, doxorubicin, eflornithine, fluorouracil, mechlorethamine, melphalan, mitomycin, nitrosoureas, vinblastine, vincristine)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;996&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1042&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1143&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1434&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1435&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1436&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1437&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1438&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1439&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HCV antivirals</p><p>Boceprevir: In vitro evidence of additive effects with interferon alfa-2b against HCV; no in vitro evidence of antagonism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;185&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Simeprevir: In vitro evidence of synergistic effects with interferon alfa against HCV;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; no in vitro evidence of antagonism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;187&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sofosbuvir: No in vitro evidence of antagonistic anti-HCV effects with interferon alfa&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;188&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Telaprevir: No in vitro evidence of antagonistic anti-HCV effects with interferon alfa&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;184&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Myelosuppressive agents</p><p>Increased risk of myelosuppression&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;398&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use concomitantly with caution;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;398&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; monitor WBC count&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phenobarbital</p><p>Possible increased phenobarbital concentrations and toxicity (e.g., lethargy, fatigue)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;863&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Radiation therapy</p><p>May result in severe toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;235&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;522&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;523&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;936&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;937&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;938&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;939&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Close monitoring advised&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;523&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ribavirin</p><p>Possible additive hematologic toxicity (anemia)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant use with oral ribavirin contraindicated if Cl<sub>cr</sub> &lt;50 mL/minute&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Telbivudine</p><p>Increased risk and severity of peripheral neuropathy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of concomitant telbivudine and any interferon for treatment of chronic HBV infection not established&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Theophylline</p><p>Increased theophylline concentrations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;950&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Vinca alkaloids (vinblastine, vincristine)</p><p>Possible increased toxicity of interferon alfa &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;156&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;299&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;332&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;333&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;336&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;385&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;394&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;459&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;931&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;932&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1700&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1732&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increased incidence of neurotoxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;487&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Zidovudine</p><p>Increased risk of hematologic (e.g., neutropenia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1051&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; thrombocytopenia)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and hepatic toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use concomitantly with caution;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; monitor WBC count&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Interferon Alfa Pharmacokinetics</h2><h3>Absorption</h3><p>Interferon alfa is well absorbed following IM or sub-Q injection;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;409&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; mean serum concentrations following IM injection comparable to those following sub-Q injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV administration (interferon alfa-2b), peak serum concentrations achieved in 30 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IM or sub-Q injection (interferon alfa-2b), peak serum concentrations achieved in 3–12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following intralesional injection (interferon alfa-2b dosage of 3 million units weekly per wart for 4 weeks), serum concentrations of the drug ranged from 5–40 units/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Peak serum concentrations reported to occur in 6 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following intralesional injection into anogenital warts (interferon alfa-n3), plasma concentrations of interferon were undetectable (detection limit 3 units/mL);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; some systemic absorption apparently occurs because adverse systemic effects were reported in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Interferons are widely and rapidly distributed into body tissues after systemic administration; highest concentrations occur in spleen, kidney, liver, and lung.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Does not readily distribute into CSF following systemic administration of mixtures of naturally occurring human or recombinant interferons;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;42&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;409&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;413&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;414&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;421&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; low concentrations detected in CSF following administration of large systemic doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;42&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;414&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;434&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether interferon crosses the placenta in humans.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;88&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk in mice;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;975&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; not known whether interferon distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Interferon alfa appears to be metabolized principally in the kidney.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;43&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;436&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;444&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;446&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;447&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hepatic metabolism and subsequent biliary excretion may be a minor pathway.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;984&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa generally undetectable or present only in trace quantities in urine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;43&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;436&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;983&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV infusion (interferon alfa-2b): 2 hours (range: 0.5–2.9 hours).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;144&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IM or sub-Q injection (interferon alfa-2b): 2–3 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Limited data indicate that serum concentrations and clearance of interferon not substantially altered in those with chronic renal failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May accumulate in body fluids of patients with markedly depressed GFR and Cl<sub>cr</sub>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Interferon alfa-2b (Intron<sup></sup> A) multiple-dose vials: 2–8°C; do not freeze or expose to heat.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; After initial dose is given, discard any solution remaining in vial after 1 month.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3 (Alferon N<sup></sup>): 2–8°C; protect from freezing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b (Intron<sup></sup> A): 2–8°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use immediately after reconstitution; may be stored at 2–8°C for up to 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions and Spectrum</h2><ul>
<li>
<p>Interferon alfa is a naturally occurring protein with antiviral, antineoplastic, and immunomodulating activity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;47&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;70&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;456&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;648&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;714&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;717&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;719&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;740&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;906&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1426&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Commercially available in US as interferon alfa-2b&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and interferon alfa-n3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Interferon alfa-2b (Intron<sup></sup> A): Single interferon subtype; recombinant preparation obtained from bacterial fermentation of <i>Escherichia coli</i> containing a genetically engineered plasmid with a human interferon alfa-2b gene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Interferon alfa-n3 (Alferon<sup></sup> N): Mixture of naturally occurring human interferon alfa proteins; precise subtype composition not determined; manufactured from pooled units of human leukocytes induced by incomplete infection with a murine virus (Sendai virus) to produce interferon alfa-n3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Mechanisms of action of interferon alfa not fully elucidated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1174&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1176&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1461&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Interferons bind to specific membrane receptors on cell surfaces&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;78&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;989&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1426&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1463&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1464&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and initiate a complex sequence of intracellular events, including induction of certain enzymes, suppression of cell proliferation, various immunomodulating activities, and inhibition of viral replication in virus-infected cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;55&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;63&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;71&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;78&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;533&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;534&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Interferon alfa is a naturally occurring protein with antiviral, antineoplastic, and immunomodulating activity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;47&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;70&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;456&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;648&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;714&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;717&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;719&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;740&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;906&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1426&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Commercially available in US as interferon alfa-2b&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and interferon alfa-n3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-2b (Intron<sup></sup> A): Single interferon subtype; recombinant preparation obtained from bacterial fermentation of <i>Escherichia coli</i> containing a genetically engineered plasmid with a human interferon alfa-2b gene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon alfa-n3 (Alferon<sup></sup> N): Mixture of naturally occurring human interferon alfa proteins; precise subtype composition not determined; manufactured from pooled units of human leukocytes induced by incomplete infection with a murine virus (Sendai virus) to produce interferon alfa-n3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mechanisms of action of interferon alfa not fully elucidated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1174&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1176&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1461&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferons bind to specific membrane receptors on cell surfaces&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;78&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;989&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1426&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1463&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1464&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and initiate a complex sequence of intracellular events, including induction of certain enzymes, suppression of cell proliferation, various immunomodulating activities, and inhibition of viral replication in virus-infected cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;55&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;63&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;71&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;78&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;533&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;534&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1177&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Advise patients receiving interferon alfa about appropriate use of the drug and the expected benefits and risks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of reading the manufacturer's patient information and medication guide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If patient and/or their caregiver is to administer IM or sub-Q interferon alfa, provide careful instructions on proper administration methods, disposal procedures, and the importance of not reusing needles and syringes; provide patient with manufacturer's instructions for use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Caution patients not to change brands of interferon alfa without consulting their clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of remaining well hydrated, especially during initial treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients with HCV infection that it is not known whether interferon alfa (alone or in conjunction with oral ribavirin) will prevent transmission of HCV infection to others or prevent long-term HCV-associated complications (cirrhosis, liver failure, liver cancer).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of taking precautions to prevent transmission of HCV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that laboratory evaluations are required before starting and periodically during treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that hives, generalized urticaria, chest tightness, wheezing, and hypotension may be early signs of hypersensitivity reactions and that they should notify their clinician if any of these conditions occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of reporting any sign or symptom of depression or suicidal ideation to clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients that the drug may need to be immediately discontinued and psychiatric intervention instituted in severe cases.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients to maintain good oral hygiene, including brushing their teeth twice daily and rinsing their mouth after vomiting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that some adverse effects (e.g., fatigue, impaired concentration) may impair ability to perform certain tasks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients of the teratogenic/embryocidal risks associated with concomitant oral ribavirin and the necessity for females of childbearing potential and male patients with female partners of childbearing age to practice effective contraception during and for 6 months after ribavirin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Advise patients receiving interferon alfa about appropriate use of the drug and the expected benefits and risks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of reading the manufacturer's patient information and medication guide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If patient and/or their caregiver is to administer IM or sub-Q interferon alfa, provide careful instructions on proper administration methods, disposal procedures, and the importance of not reusing needles and syringes; provide patient with manufacturer's instructions for use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution patients not to change brands of interferon alfa without consulting their clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of remaining well hydrated, especially during initial treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients with HCV infection that it is not known whether interferon alfa (alone or in conjunction with oral ribavirin) will prevent transmission of HCV infection to others or prevent long-term HCV-associated complications (cirrhosis, liver failure, liver cancer).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of taking precautions to prevent transmission of HCV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that laboratory evaluations are required before starting and periodically during treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that hives, generalized urticaria, chest tightness, wheezing, and hypotension may be early signs of hypersensitivity reactions and that they should notify their clinician if any of these conditions occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of reporting any sign or symptom of depression or suicidal ideation to clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients that the drug may need to be immediately discontinued and psychiatric intervention instituted in severe cases.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients to maintain good oral hygiene, including brushing their teeth twice daily and rinsing their mouth after vomiting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that some adverse effects (e.g., fatigue, impaired concentration) may impair ability to perform certain tasks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients of the teratogenic/embryocidal risks associated with concomitant oral ribavirin and the necessity for females of childbearing potential and male patients with female partners of childbearing age to practice effective contraception during and for 6 months after ribavirin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For injection</p><p>10 million units</p><p>Intron<sup></sup> A (available as single-dose vials with sterile water for injection diluent)</p><p>Schering</p><p>18 million units</p><p>Intron<sup></sup> A (available as single-dose vials with sterile water for injection diluent)</p><p>Schering</p><p>50 million units</p><p>Intron<sup></sup> A (available as single-dose vials with sterile water for injection diluent)</p><p>Schering</p><p>Injection</p><p>6 million units/mL (18 million units)</p><p>Intron<sup></sup> A (available as multiple-dose vials)</p><p>Schering</p><p>10 million units/mL (25 million units)</p><p>Intron<sup></sup> A (available as multiple-dose vials)</p><p>Schering</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection</p><p>5 million units/mL</p><p>Alferon N<sup></sup> (with albumin human and phenol)</p><p>Hemispherx</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions October 30, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>2. Schering Corporation. Intron<sup></sup> A (interferon alfa-2b, recombinant) for injection prescribing information. Whitehouse Station, NJ; 2014 Apr.</p><p>3. Hemispherx Biopharma. Alferon N injection<sup></sup> (interferon alfa-n3 [human leukocyte derived]) prescribing information. Philadelphia, PA; 2004 Jul.</p><p>5. Houglum JE. Interferon: mechanisms of action and clinical value. <i>Clin Pharm</i>. 1983; 2:20-8. http://www.ncbi.nlm.nih.gov/pubmed/6192965?dopt=AbstractPlus</p><p>6. Farci P, Mandas A, Coiana A et al. Treatment of chronic hepatitis D with interferon alfa-2a. <i>N Engl J Med</i>. 1994; 330:88-94. http://www.ncbi.nlm.nih.gov/pubmed/8259188?dopt=AbstractPlus</p><p>8. Borden EC, Edwards BS, Hawkins MJ et al. Interferons: biological response modification and pharmacology. In: Mihich E, ed. Biological response in cancer: progress toward potential applications. New York: Plenum Press; 1982:169-218.</p><p>9. Balmer CM. The new alpha interferons. <i>Drug Intell Clin Pharm</i>. 1985; 19:887-93. http://www.ncbi.nlm.nih.gov/pubmed/3910384?dopt=AbstractPlus</p><p>11. Foon KA, Sherwin SA, Abrams PG et al. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. <i>N Engl J Med</i>. 1984; 311:1148-52. http://www.ncbi.nlm.nih.gov/pubmed/6482933?dopt=AbstractPlus</p><p>12. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. <i>Gastroenterology</i>. 2001; 120:1828-53. http://www.ncbi.nlm.nih.gov/pubmed/11375963?dopt=AbstractPlus</p><p>13. Schering-Plough Corporation. Interferon backgrounder. Kenilworth, NJ; 1988 May.</p><p>14. Perrillo RP, Schiffer, Davis GL et al and the Hepatitis Interventional Therapy Group. A randomized, control trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. <i>N Engl J Med</i>. 1990; 323:295-301. http://www.ncbi.nlm.nih.gov/pubmed/2195346?dopt=AbstractPlus</p><p>15. Hanley DF, Wiranowska-Stewart M, Stewart WE. Pharmacology of interferons: I. Pharmacologic distinctions between human leukocyte and fibroblast interferons. <i>Int J Immunopharmacol</i>. 1979; 1:219-26. http://www.ncbi.nlm.nih.gov/pubmed/95249?dopt=AbstractPlus</p><p>16. Wong DKH, Cheung AM, O’apos;Rourke K et al. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. <i>Ann Intern Med</i>. 1993; 119:312-23. http://www.ncbi.nlm.nih.gov/pubmed/8328741?dopt=AbstractPlus</p><p>17. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. <i>MMWR Recomm Rep</i>. 2010; 59(RR-12):1-110. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm</p><p>18. Larsson A, Forsgren M, Hard af Segerstad S et al. Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis. <i>Acta Paediatr Scand</i>. 1976; 65:105-10. http://www.ncbi.nlm.nih.gov/pubmed/1251716?dopt=AbstractPlus</p><p>20. Genentech. Pegasys<sup></sup> (peginterferon alfa-2a) injection for subcutaneous use prescribing information. South San Francisco, CA; 2013 Jul.</p><p>21. Emodi G, Just M, Hernandez R et al. Circulating interferon in man after administration of exogenous human leukocyte interferon. <i>J Natl Cancer Inst</i>. 1975; 54:1045- 9. http://www.ncbi.nlm.nih.gov/pubmed/1127735?dopt=AbstractPlus</p><p>23. De Clercq E, Edy VG, De Vlieger H et al. Intrathecal administration of interferon in neonatal herpes. <i>J Pediatr</i>. 1975; 86:736-9. http://www.ncbi.nlm.nih.gov/pubmed/166151?dopt=AbstractPlus</p><p>25. Perez V, Tanno H, Villamil F et al. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. <i>J Hepatol</i>. 1990; 11:S113-5. http://www.ncbi.nlm.nih.gov/pubmed/2079567?dopt=AbstractPlus</p><p>26. USP DI: drug information for the health care professional. Johnson KW, ed. 10th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1990; 1B:1561-5.</p><p>27. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. <i>Gastroenterology</i>. 1998; 114:988-95. http://www.ncbi.nlm.nih.gov/pubmed/9558288?dopt=AbstractPlus</p><p>28. Greischel A, Tanswell P, Busch U et al. Pharmacokinetics and biodistribution of recombinant human interferon-α2C in rat and marmoset. <i>Arzneim Forsch</i>. 1988; 38:1539-43.</p><p>29. Wills RJ, Dennis S, Spiegel H et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. <i>Clin Pharmacol Ther</i>. 1984; 35:722-7. http://www.ncbi.nlm.nih.gov/pubmed/6713784?dopt=AbstractPlus</p><p>30. Smith RA, Norris F, Palmer D et al. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic circulation. <i>Clin Pharmacol Ther</i>. 1985; 37:85-8. http://www.ncbi.nlm.nih.gov/pubmed/3965239?dopt=AbstractPlus</p><p>31. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. <i>Br J Clin Pharmacol</i>. 1986; 22:610-2. http://www.ncbi.nlm.nih.gov/pubmed/3790409?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1401186&amp;blobtype=pdf</p><p>32. Wills RJ, Soike KF. Pharmacokinetics of human recombinant interferon-αI after IV infusion and im injection in African green monkeys. <i>J Interferon Res</i>. 1988; 8:427-32. http://www.ncbi.nlm.nih.gov/pubmed/3171243?dopt=AbstractPlus</p><p>34. Billiau A. Interferon therapy: pharmacokinetic and pharmacological aspects. <i>Arch Virol</i>. 1981; 67:121-33. http://www.ncbi.nlm.nih.gov/pubmed/6163417?dopt=AbstractPlus</p><p>35. Anon. Interferon plus ribavirin for chronic hepatitis C. <i>Med Lett Drugs Ther</i>. 1999; 41:53-4. http://www.ncbi.nlm.nih.gov/pubmed/10368698?dopt=AbstractPlus</p><p>36. McHutchison JG, Gordon SC, Schiffer et al for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. <i>N Engl J Med</i>. 1998; 339:1485-92. http://www.ncbi.nlm.nih.gov/pubmed/9819446?dopt=AbstractPlus</p><p>37. Poynard T, Marcellin P, Lee SS et al for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. <i>Lancet</i>. 1998; 352:1426-32. http://www.ncbi.nlm.nih.gov/pubmed/9807989?dopt=AbstractPlus</p><p>38. Davis GL, Esteban-Mur R, Rustgi V et al Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. <i>N Engl J Med</i>. 1998; 339:1493-9.</p><p>39. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. <i>Lancet</i>. 2001; 358:958-65. http://www.ncbi.nlm.nih.gov/pubmed/11583749?dopt=AbstractPlus</p><p>41. Renton KW, Mannering GJ. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. <i>Biochem Biophys Res Commun</i>. 1976; 73:343-8. http://www.ncbi.nlm.nih.gov/pubmed/187194?dopt=AbstractPlus</p><p>42. Martino S, Singhakowinta A. Serial interferon alpha<sub>2</sub> levels in serum and cerebrospinal fluid. <i>Cancer Treat Rep</i>. 1984; 68:1057-8. http://www.ncbi.nlm.nih.gov/pubmed/6744344?dopt=AbstractPlus</p><p>43. Sumpio BE, Ernstoff MS, Kirkwood JM. Urinary excretion of interferon, albumin, and β<sub>2</sub>-microglobulin during interferon treatment. <i>Cancer Res</i>. 1984; 44:3599-603. http://www.ncbi.nlm.nih.gov/pubmed/6378373?dopt=AbstractPlus</p><p>44. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. <i>Can Med Assoc J</i>. 1980; 123:288-90. http://www.ncbi.nlm.nih.gov/pubmed/7260771?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1704744&amp;blobtype=pdf</p><p>45. Bocci V, Pacini A, Muscettola M et al. The kidney is the main site of interferon catabolism. J Interferon Res. 1982; 2:309-14.</p><p>46. Bocci V, Pacini A, Bandinelli L et al. The role of the liver in the catabolism of human α- and β- interferon. <i>J Gen Virol</i>. 1982; 60:397-400. http://www.ncbi.nlm.nih.gov/pubmed/6180128?dopt=AbstractPlus</p><p>47. WHO Expert Committee on Biological Standardization. World Health Organization Technical Report Series, 771. 38th Report; World Health Organization, Geneva, 1988:29-32,37-87.</p><p>48. Schering Corporation. PegIntron<sup></sup> (peginterferon alfa-2b) injection, for subcutaneous use prescribing information. Whitehouse Station, NJ; 2014 Jul.</p><p>49. Schering Corporation. Sylatron<sup></sup> (peginterferon alfa-2b) for injection, for subcutaneous use prescribing information. Whitehouse Station, NJ; 2013 Dec.</p><p>52. Comanor L, Minor J, Conjeevaram HS et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. <i>J Viral Hepat</i>. 2001; 8:139-47. http://www.ncbi.nlm.nih.gov/pubmed/11264734?dopt=AbstractPlus</p><p>56. Gursoy M, Gur G, Arslan H et al. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. <i>J Viral Hepat</i>. 2001; 8:70-7. http://www.ncbi.nlm.nih.gov/pubmed/11155154?dopt=AbstractPlus</p><p>55. Branca AA, Faltynek CR, D’Alessandro SB et al. Interaction of interferon with cellular receptors—internalization and degradation of cell-bound interferon. <i>J Biol Chem</i>. 1982; 257:13291-6. http://www.ncbi.nlm.nih.gov/pubmed/6292184?dopt=AbstractPlus</p><p>63. Smyth JF. Guidelines for the use of Intron A (interferon alfa-2b) in clinical oncology: lessons from the laboratory. <i>Cancer Treat Rev</i>. 1988; 15(Suppl A):3-6. http://www.ncbi.nlm.nih.gov/pubmed/3342417?dopt=AbstractPlus</p><p>68. Peterson LR, Marfin AA. West Nile virus: a primer for the clinician. <i>Ann Intern Med</i>. 2002; 137:173-9. http://www.ncbi.nlm.nih.gov/pubmed/12160365?dopt=AbstractPlus</p><p>70. Tovey MG. Interferon: immunomodulator and antitumor agent. In: Fudenberg H, Whiten HD, Ambrogi F, eds. Immunoregulation: new frontiers and advances. New York: Plenum Press; 1984:155-9.</p><p>71. Oldham RK. Biologicals for cancer treatment: interferons. <i>Hosp Pract</i>. 1985; 20:71-91.</p><p>77. Borden EC. Effects of interferons in neoplastic diseases of man. <i>Pharmacol Ther</i>. 1988; 37:213-29. http://www.ncbi.nlm.nih.gov/pubmed/2455301?dopt=AbstractPlus</p><p>78. Zoon KC, Arnheiter H. Studies of the interferon receptors. <i>Pharmacol Ther</i>. 1984; 24:259-78. http://www.ncbi.nlm.nih.gov/pubmed/6205408?dopt=AbstractPlus</p><p>88. Manufacturer’s comments (personal observations)</p><p>92. Weiskittel PD. West nile virus infection in a renal transplant recipient. <i>Nephrol Nurs J</i>. 2004; 31:327-9. http://www.ncbi.nlm.nih.gov/pubmed/15303427?dopt=AbstractPlus</p><p>93. Sayao AL, Suchowersky O, Al-Khathaami A et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. <i>Can J Neurol Sci</i>. 2004; 31:194-203. http://www.ncbi.nlm.nih.gov/pubmed/15198443?dopt=AbstractPlus</p><p>94. Kalil AC, Devetten MP, Singh S et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. <i>Clin Infect Dis</i>. 2005; 40:764-6. http://www.ncbi.nlm.nih.gov/pubmed/15714427?dopt=AbstractPlus</p><p>97. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. AASLD practice guidelines. Sep 2009. From AASLD website. http://www.aasld.org</p><p>99. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. <i>J Viral Hepat</i>. 2005; 12:2-9. http://www.ncbi.nlm.nih.gov/pubmed/15655042?dopt=AbstractPlus</p><p>100. Rosina F, Pintus C, Meschievitz C et al. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. <i>Hepatology</i>. 1991; 13:1052-6. http://www.ncbi.nlm.nih.gov/pubmed/2050321?dopt=AbstractPlus</p><p>101. Di Marco V, Giacchino R, Timitilli A et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. <i>J Viral Hepat</i>. 1996; 3:123-8. http://www.ncbi.nlm.nih.gov/pubmed/8871870?dopt=AbstractPlus</p><p>102. Farci P, Roskams T, Chessa L et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. <i>Gastroenterology</i>. 2004; 126:1740-9. http://www.ncbi.nlm.nih.gov/pubmed/15188169?dopt=AbstractPlus</p><p>104. Renton KW, Singh G, Stebbing N. Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450. <i>Biochem Pharmacol</i>. 1984; 33:3899-902. http://www.ncbi.nlm.nih.gov/pubmed/6508841?dopt=AbstractPlus</p><p>105. Singh G, Renton KW. Inhibition of the synthesis of hepatic cytochrome P-450 by the interferon-inducing agent poly rI.rCi. <i>Can J Physiol Pharmacol</i>. 1984; 62:379-83. http://www.ncbi.nlm.nih.gov/pubmed/6733584?dopt=AbstractPlus</p><p>106. Jonkman JHG, Nicholson KG, Farrow PR et al. Effects of α-interferon on theophylline pharmacokinetics and metabolism. <i>Br J Clin Pharmacol</i>. 1989; 27:795-802. http://www.ncbi.nlm.nih.gov/pubmed/2757895?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1379807&amp;blobtype=pdf</p><p>107. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. <i>Lancet</i>. 1987; 2:939-41. http://www.ncbi.nlm.nih.gov/pubmed/2444839?dopt=AbstractPlus</p><p>108. Williams SJ, Baird-Lambert J, Cantrill EM et al. Interferon inhibits hepatic clearance of theophylline by a non competitive mechanism. <i>Aust N Z J Med</i>. 1987; 17(Suppl 1):128.</p><p>109. Taylor G, Marafino BJ Jr, Moore JA et al. Interferon reduces hepatic drug metabolism in vivo in mice. <i>Drug Metab Dispos</i>. 1985; 13:459-63. http://www.ncbi.nlm.nih.gov/pubmed/2863111?dopt=AbstractPlus</p><p>110. Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. <i>Ann Intern Med</i>. 2009; 150:104-10. http://www.ncbi.nlm.nih.gov/pubmed/19124811?dopt=AbstractPlus</p><p>111. González-Peralta RP, Kelly DA, Haber B et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. <i>Hepatology</i>. 2005; 42:1010-8. http://www.ncbi.nlm.nih.gov/pubmed/16250032?dopt=AbstractPlus</p><p>112. Schering Corporation. Intron<sup></sup> A (interferon alfa-2b, recombinant) for injection medication guide. Whitehouse Station, NJ; 2011 Feb.</p><p>113. Aguet M, Blanchard B. High affinity binding of<sup>125</sup>I-labeled mouse interferon to a specific cell surface receptor: II. Analysis of binding properties. <i>Virology</i>. 1981; 115:249-61. http://www.ncbi.nlm.nih.gov/pubmed/6171930?dopt=AbstractPlus</p><p>114. Aguet M. High-affinity binding of<sup>125</sup>I-labelled mouse interferon to a specific cell surface receptor. <i>Nature</i>. 1980; 284:459-61. http://www.ncbi.nlm.nih.gov/pubmed/6444699?dopt=AbstractPlus</p><p>115. Schering Corporation. Intron<sup></sup> A (interferon alfa-2b, recombinant) for injection instructions for use. Whitehouse Station, NJ; 2011 Feb.</p><p>119. American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C. From the AASLD website. http://www.hcvguidelines.org/</p><p>120. Lin TI, Lenz O, Fanning G et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. <i>Antimicrob Agents Chemother</i>. 2009; 53:1377-85. http://www.ncbi.nlm.nih.gov/pubmed/19171797?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2663092&amp;blobtype=pdf</p><p>122. Foon KA, Maluish AE, Abrams PG et al. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. <i>Am J Med</i>. 1986; 80:351-6. http://www.ncbi.nlm.nih.gov/pubmed/3953613?dopt=AbstractPlus</p><p>123. Golomb HM. Interferons: present and future use in cancer therapy. <i>J Clin Oncol</i>. 1986; 4:123-5. http://www.ncbi.nlm.nih.gov/pubmed/2418165?dopt=AbstractPlus</p><p>124. Golomb HM, Jacobs A, Fefer A et al. Alpha-2 interferon therapy of hairy cell leukemia: a multicenter study of 64 patients. <i>J Clin Oncol</i>. 1986; 4:900-5. http://www.ncbi.nlm.nih.gov/pubmed/3519880?dopt=AbstractPlus</p><p>125. Golomb HM, Ratain MJ, Fefer A et al. Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. <i>J Natl Cancer Inst</i>. 1988; 80:369-73. http://www.ncbi.nlm.nih.gov/pubmed/3282078?dopt=AbstractPlus</p><p>126. Golomb HM, Fefer A, Golde DW et al. Report of a multi- institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. <i>Semin Oncol</i>. 1988; 15(Suppl 5):7-9. http://www.ncbi.nlm.nih.gov/pubmed/3057646?dopt=AbstractPlus</p><p>127. Grem JL, King SA, Cheson BD et al. Pentostatin in hairy cell leukemia: treatment by the special exception mechanism. <i>J Natl Cancer Inst</i>. 1989; 81:448-53. http://www.ncbi.nlm.nih.gov/pubmed/2783980?dopt=AbstractPlus</p><p>128. Henderson ES, Han T. Current therapy of acute and chronic leukemia in adults. <i>CA Cancer J Clin</i>. 1986; 36:322-50. http://www.ncbi.nlm.nih.gov/pubmed/3096521?dopt=AbstractPlus</p><p>129. Hoffmann V, Frey B. Long-term treatment of hairy cell leukemia with interferon alfa-2b. <i>Cancer Treat Rev</i>. 1988; 15(Suppl A):7-13. http://www.ncbi.nlm.nih.gov/pubmed/3342418?dopt=AbstractPlus</p><p>130. Triantos C, Kalafateli M, Nikolopoulou V et al. Meta-analysis: antiviral treatment for hepatitis D. <i>Aliment Pharmacol Ther</i>. 2012; 35:663-73. http://www.ncbi.nlm.nih.gov/pubmed/22273482?dopt=AbstractPlus</p><p>131. Jacobs AD, Champlin RE, Golde DW. Recombinant α-2- interferon for hairy cell leukemia. <i>Blood</i>. 1985; 65:1017-20. http://www.ncbi.nlm.nih.gov/pubmed/3884059?dopt=AbstractPlus</p><p>132. Moormeier JA, Ratain MJ, Westbrook CA et al. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. <i>J Natl Cancer Inst</i>. 1989; 81:1172-4. http://www.ncbi.nlm.nih.gov/pubmed/2746669?dopt=AbstractPlus</p><p>134. Niederle N, Kummer G. The role of interferon in the management of patients with hairy cell leukemia and multiple myeloma. In: Berger HG, Buchler M, Rusfeld RA et al, eds. Cancer therapy—monoclonal antibodies, lymphokines: new developments in surgical oncology and chemotherapy and hormonal therapy. Berlin: Springer, Verlag; 1989.</p><p>135. Ozer H, Golomb HM, Zimmerman H et al. Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia. <i>J Natl Cancer Inst</i>. 1989; 81:594-602. http://www.ncbi.nlm.nih.gov/pubmed/2495367?dopt=AbstractPlus</p><p>136. Pagnucco G, Castelli G, Lazzarino M et al. Human lymphoblastoid interferon in the treatment of hairy cell leukaemia. <i>Int J Immunother</i>. 1988; IV:169-75.</p><p>138. Quesada JR, Gutterman JU, Hersh EM. Treatment of hairy cell leukemia with alpha interferons. <i>Cancer</i>. 1986; 57:1678-80. http://www.ncbi.nlm.nih.gov/pubmed/3948137?dopt=AbstractPlus</p><p>140. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. <i>Lancet</i>. 2011; 378:73-85. http://www.ncbi.nlm.nih.gov/pubmed/21511329?dopt=AbstractPlus</p><p>141. Abbas Z, Khan MA, Salih M et al. Interferon alpha for chronic hepatitis D. <i>Cochrane Database Syst Rev</i>. 2011; :CD006002. http://www.ncbi.nlm.nih.gov/pubmed/22161394?dopt=AbstractPlus</p><p>142. Golomb HM, Ratain MJ. Recent advances in the treatment of hairy-cell leukemia. <i>N Engl J Med</i>. 1987; 316:870-2. http://www.ncbi.nlm.nih.gov/pubmed/2434851?dopt=AbstractPlus</p><p>143. Spiers ASD, Moore D, Cassileth PA et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). <i>N Engl J Med</i>. 1987; 316:825-30. http://www.ncbi.nlm.nih.gov/pubmed/2434850?dopt=AbstractPlus</p><p>144. Spiegel RJ. Intron-A (interferon alfa-2b): clinical overview. <i>Cancer Treat Rev</i>. 1985; 12(Suppl B):5-16. http://www.ncbi.nlm.nih.gov/pubmed/3914355?dopt=AbstractPlus</p><p>145. De Wit R, Schattenkerk JKME, Boucher CAB et al. Clinical and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi’s sarcoma. <i>Lancet</i>. 1988; 2:1214-7. http://www.ncbi.nlm.nih.gov/pubmed/2903953?dopt=AbstractPlus</p><p>147. Kurzrock R, Rosenblum MG, Quesada JR et al. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. <i>J Clin Oncol</i>. 1986; 4:1677-83. http://www.ncbi.nlm.nih.gov/pubmed/3095504?dopt=AbstractPlus</p><p>148. Groopman JE, Gottlieb MS, Goodman J et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. <i>Ann Intern Med</i>. 1984; 100:671-6. http://www.ncbi.nlm.nih.gov/pubmed/6712031?dopt=AbstractPlus</p><p>149. Kovacs JA, Deyton L, Davey R et al. Combined zidovudine and interferon-α therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). <i>Ann Intern Med</i>. 1989; 111:280-7. http://www.ncbi.nlm.nih.gov/pubmed/2757312?dopt=AbstractPlus</p><p>150. Hirsch MS, Tolkoff-Rubin NE, Kelly AP et al. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing dialysis. J Infect Dis. 1983; 148:335.</p><p>152. Scadden DT, Groopman JE. Kaposi sarcoma and alpha- interferon therapy. <i>Ann Intern Med</i>. 1989; 111:186-7.</p><p>153. Nightingale SL. Interferon alfa approved for Kaposi’s sarcoma. <i>JAMA</i>. 1989; 261:350. http://www.ncbi.nlm.nih.gov/pubmed/2909766?dopt=AbstractPlus</p><p>154. Krown SE, Real FX, Vadhan-Raj S et al. Kaposi’s sarcoma and the acquired immune deficiency syndrome: treatment with recombinant interferon alpha and analysis of prognostic factors. <i>Cancer</i>. 1986; 57:1662-5. http://www.ncbi.nlm.nih.gov/pubmed/3081247?dopt=AbstractPlus</p><p>155. Lane HC, Kovacs JA, Feinberg J et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi’s sarcoma. <i>Lancet</i>. 1988; 2:1218-22. http://www.ncbi.nlm.nih.gov/pubmed/2903954?dopt=AbstractPlus</p><p>156. Groopman JE, Scadden DT. Interferon therapy for Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). <i>Ann Intern Med</i>. 1989; 110:335-7. http://www.ncbi.nlm.nih.gov/pubmed/2644884?dopt=AbstractPlus</p><p>158. Wickramasinghe L, Hindson TC, Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. <i>J Am Acad Dermatol</i>. 1989; 20:71-4. http://www.ncbi.nlm.nih.gov/pubmed/2913082?dopt=AbstractPlus</p><p>159. Hilfenhaus J, Weinmann E, Majer M et al. Administration of human interferon to rabies virus-infected monkeys after exposure. <i>J Infect Dis</i>. 1977; 135:846-9. http://www.ncbi.nlm.nih.gov/pubmed/404370?dopt=AbstractPlus</p><p>163. Reichman RC, Oakes D, Bonnez W et al. Treatment of condyloma acuminatum with three different interferons administered intralesionally: a double-blind, placebo-controlled trial. <i>Ann Intern Med</i>. 1988; 108:675-9. http://www.ncbi.nlm.nih.gov/pubmed/3358568?dopt=AbstractPlus</p><p>164. Sonnenfeld G, Harned CL, Thaniyavarn S et al. Type II interferon induction and passive transfer depress the murine cytochrome P-450 drug metabolism system. <i>Antimicrob Agents Chemother</i>. 1980; 17:969-72. http://www.ncbi.nlm.nih.gov/pubmed/6157362?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=283913&amp;blobtype=pdf</p><p>165. Jordan GW, Fried RP, Merrigan TC. Administration of human leukocyte interferon in herpes zoster: I. Safety, circulating antiviral activity, and host responses to infection. <i>J Infect Dis</i>. 1974; 130:56-62. http://www.ncbi.nlm.nih.gov/pubmed/4601181?dopt=AbstractPlus</p><p>170. Groopman JE. Therapeutic options in hairy-cell leukemia. <i>Semin Oncol</i>. 1985; 12(Suppl 5):30-4. http://www.ncbi.nlm.nih.gov/pubmed/3909417?dopt=AbstractPlus</p><p>171. Ratain MJ, Vardiman JW, Golomb HM. The role of interferon in the treatment of hairy cell leukemia. <i>Semin Oncol</i>. 1986: XIII(Suppl 2):21-8.</p><p>172. Weck PK, Leventhal BG, Brand C et al. Detection and incidence of neutralizing antibodies to interferon-alpha-n1. <i>J Interferon Res</i>. 1989; 9(Suppl 1):S37-43. http://www.ncbi.nlm.nih.gov/pubmed/2553830?dopt=AbstractPlus</p><p>177. Sen GC. Biochemical pathways in interferon—action. <i>Pharmacol Ther</i>. 1984; 24:235-57. http://www.ncbi.nlm.nih.gov/pubmed/6205407?dopt=AbstractPlus</p><p>178. Brünig K, Fülle HH, Dahmen E et al. Therapy of hairy cell leukemia with interferon. <i>Onkologie</i>. 1988; 4:159-65.</p><p>179. Thompson JA, Kidd P, Rubin E et al. Very low dose α- 2b interferon for the treatment of hairy cell leukemia. <i>Blood</i>. 1989; 73:1440-3. http://www.ncbi.nlm.nih.gov/pubmed/2713488?dopt=AbstractPlus</p><p>181. Hasselbalch H, Braide I, Lisse I et al. Recombinant interferon-alfa-2b treatment of hairy-cell leukemia: experience with a low dose schedule. <i>Eur J Haematol</i>. 1988; 41:438- 44. http://www.ncbi.nlm.nih.gov/pubmed/3061836?dopt=AbstractPlus</p><p>182. Ratain MJ, Golomb HM, Vardiman JW et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. <i>J Clin Oncol</i>. 1988; 6:1714-21. http://www.ncbi.nlm.nih.gov/pubmed/3054003?dopt=AbstractPlus</p><p>186. Ehmann WC, Silber R. Recombinant alpha-2 interferon for treatment of hairy cell leukemia without prior splenectomy. <i>Am J Med</i>. 1986; 80:1111-14. http://www.ncbi.nlm.nih.gov/pubmed/3728508?dopt=AbstractPlus</p><p>184. Vertex Pharmaceuticals Incorporated. Incivek<sup></sup> (telaprevir) tablets prescribing information. Cambridge, MA; 2013 Oct.</p><p>185. Merck Sharp &amp; Dohme Corporation. Victrelis<sup></sup> (boceprevir) capsules prescribing information. Whitehouse Station, NJ; 2014 Jul.</p><p>187. Janssen Therapeutics. Olysio<sup></sup> (simeprevir) capsules prescribing information. Titusville, NJ; 2013 Nov.</p><p>188. Gilead Sciences, Inc. Sovaldi<sup></sup> (sofosbuvir) tablets prescribing information. Foster City, CA; 2013 Dec.</p><p>190. Kaplan JE, Benson C, Holmes KH et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recomm Rep</i>. 2009; 58(RR-4):1-207; quiz CE1-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2821196&amp;blobtype=pdf http://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf</p><p>191. Hood LE. Interferon: getting in the way of viruses and tumors. <i>Am J Nurs</i>. 1987; 87:459-65. http://www.ncbi.nlm.nih.gov/pubmed/2436479?dopt=AbstractPlus</p><p>192. Gibson J, Cameron K, Gallagher K et al. Clinical response of hairy-cell leukaemia to interferon-α: results of an Australian study. 1988; 149:293-6.</p><p>193. Maziarz RT, Tepler I, Antin JH et al. Reversal of infection with <i>mycobacterium avium intracellulare</i> by treatment with alpha-interferon in a patient with hairy cell leukemia. <i>Ann Intern Med</i>. 1988; 109:292-4. http://www.ncbi.nlm.nih.gov/pubmed/3395039?dopt=AbstractPlus</p><p>194. Keller BC, Fredericksen BL, Samuel MA et al. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. <i>J Virol</i>. 2006; 80:9424-34. http://www.ncbi.nlm.nih.gov/pubmed/16973548?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1617238&amp;blobtype=pdf</p><p>195. Chan-Tack KM, Forrest G. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. <i>Scand J Infect Dis</i>. 2005; 37:944-6. http://www.ncbi.nlm.nih.gov/pubmed/16308241?dopt=AbstractPlus</p><p>196. Lewis M, Amsden JR. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. <i>Pharmacotherapy</i>. 2007; 27:455-8. http://www.ncbi.nlm.nih.gov/pubmed/17316156?dopt=AbstractPlus</p><p>198. Clemens M. Interferons and oncogenes. <i>Nature</i>. 1985; 313:531-2. http://www.ncbi.nlm.nih.gov/pubmed/2578626?dopt=AbstractPlus</p><p>199. Skotnick AB, Wolska-Smolen T, Blicharski J et al. Human recombinant interferon-alfa-2 in the treatment of patients with hairy cell leukemia. <i>Cancer Detect Prev</i>. 1988; 12:511- 22. http://www.ncbi.nlm.nih.gov/pubmed/3180143?dopt=AbstractPlus</p><p>200. Guo JT, Hayashi J, Seeger C. West Nile virus inhibits the signal transduction pathway of alpha interferon. <i>J Virol</i>. 2005; 79:1343-50. http://www.ncbi.nlm.nih.gov/pubmed/15650160?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=544142&amp;blobtype=pdf</p><p>201. Davis LE, DeBiasi R, Goade DE et al. West Nile virus neuroinvasive disease. <i>Ann Neurol</i>. 2006; 60:286-300. http://www.ncbi.nlm.nih.gov/pubmed/16983682?dopt=AbstractPlus</p><p>202. Rai KR, Davis R, Davey F et al. Splenectomy may be avoidable in patients (pts) with active hairy cell leukemia (HCL) who are responsive to alfa-2b interferon (AIF): a cancer and leukemia group B (CALGB) study. <i>Proc Am Soc Clin Oncol</i>. 1989; 8:A813.</p><p>203. Krown SE. Kaposi’s sarcoma and AIDS: the role of interferons in treatment. <i>Dev Med Virol</i>. 1988; 4:62-74.</p><p>204. Anon. Treatment of AIDS-related Kaposi’s sarcoma. <i>Am J Hosp Pharm</i>. 1989; 46:1211.</p><p>206. Volberding PA, Mitsuyasu RT, Golando JP et al. Treatment of Kaposi’s sarcoma with interferon alfa 2b (Intron<sup></sup> A). <i>Cancer</i>. 1987; 59:620-5. http://www.ncbi.nlm.nih.gov/pubmed/3492260?dopt=AbstractPlus</p><p>207. Rios A, Mansell P, Newell G et al. The use of lymphoblastoid interferon HuIFN alpha (Ly) and vinblastine in the treatment of acquired immunodeficiency syndrome (AIDS) related Kaposi’s sarcoma (KS). <i>Proc Am Soc Clin Oncol</i>. 1985; 4:6.</p><p>208. Krown SE, Real FX, Cunningham-Rundles S et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. <i>N Engl J Med</i>. 1983; 308:1071-6. http://www.ncbi.nlm.nih.gov/pubmed/6835320?dopt=AbstractPlus</p><p>210. Mayer-da-Silva A, Stadler R, Imcke E et al. Disseminated Kaposi’s sarcoma in AIDS: histogenesis-related populations and influence of long-term treatment with rIFN-αA. <i>J Invest Dermatol</i>. 1987; 89:618-24. http://www.ncbi.nlm.nih.gov/pubmed/3680987?dopt=AbstractPlus</p><p>211. Food and Drug Administration. Alpha interferon for venereal warts. <i>FDA Drug Bull</i>. 1988. 18:19-20. (IDIS 245506)</p><p>212. Gariglio M, Gribaudo G, Franco A et al. Inhibition of interferon-γ antiviral and antiproliferative activities by ras oncogene expression. <i>J Natl Cancer Inst</i>. 1989; 81:1014-20. http://www.ncbi.nlm.nih.gov/pubmed/2499691?dopt=AbstractPlus</p><p>214. Revel M, Chebath J. Interferon-activated genes. <i>Trends Biochem Sci</i>. 1986; 11:166-70.</p><p>215. Schering. Intron<sup></sup> A: interferon alfa-2b, recombinant injection product monograph. Condyloma acuminatum. Kenilworth, NJ: 1988 Jun.</p><p>216. Balkwill FR. Interferons. <i>Lancet</i>. 1989; 1:1060- 3. http://www.ncbi.nlm.nih.gov/pubmed/2469921?dopt=AbstractPlus</p><p>217. Bunn PA Jr, Foon KA, Ihde DC et al. Recombinant leukocyte A inteferon: an active agent in advanced cutaneous T- cell lymphomas. <i>Ann Intern Med</i>. 1984; 101:484-7. http://www.ncbi.nlm.nih.gov/pubmed/6332565?dopt=AbstractPlus</p><p>218. Gutterman JU, Fine S, Quesada J et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biological effects in cancer patients. <i>Ann Intern Med</i>. 1982; 96:549-56. http://www.ncbi.nlm.nih.gov/pubmed/6176159?dopt=AbstractPlus</p><p>219. Anon. Interferon for treatment of hairy-cell leukemia. <i>Med Lett Drugs Ther</i>. 1986; 28:78-80. http://www.ncbi.nlm.nih.gov/pubmed/3736496?dopt=AbstractPlus</p><p>220. Thompson JA, Brady J, Kidd P et al. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. <i>Cancer Treat Rep</i>. 1985; 69:791-3. http://www.ncbi.nlm.nih.gov/pubmed/4016788?dopt=AbstractPlus</p><p>224. Hersey P, Hasic E, MacDonald M et al. Effects of recombinant leukocyte interferon (RIFN-alfa A) on tumor growth and immune responses in patients with metastatic melanoma. <i>Br J Cancer</i>. 1985; 51:815-26. http://www.ncbi.nlm.nih.gov/pubmed/3873953?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1977086&amp;blobtype=pdf</p><p>225. Quesada JR, Rios A, Swanson D et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. <i>J Clin Oncol</i>. 1985; 3:1522-8. http://www.ncbi.nlm.nih.gov/pubmed/4056843?dopt=AbstractPlus</p><p>227. Alawattegama AB, Kinghorn GR. Bowenoid dysplasia in human papillomavirus-16 DNA positive flat condylomas during interferon-β treatment. <i>Lancet</i>. 1984; 1:1468. http://www.ncbi.nlm.nih.gov/pubmed/6145904?dopt=AbstractPlus</p><p>232. Tovey MG, Dron M, Mogensen KE et al. Isolation of Daudi cells with reduced sensistivity to interferon: II. On the mechanisms of resistance. <i>J Gen Virol</i>. 1983; 64:2649-53. http://www.ncbi.nlm.nih.gov/pubmed/6319552?dopt=AbstractPlus</p><p>235. Krown SE. Interferons and interferon inducers in cancer treatment. <i>Semin Oncol</i>. 1986; 13:207-17. http://www.ncbi.nlm.nih.gov/pubmed/2424089?dopt=AbstractPlus</p><p>236. Joshi AR, Sarkar FH, Gupta SL. Interferon receptors: cross-linking of human leukocyte interferon α-2 to its receptor on human cells. <i>J Biol Chem</i>. 1982; 257:13884-7. http://www.ncbi.nlm.nih.gov/pubmed/6292213?dopt=AbstractPlus</p><p>237. Schering. Intron<sup></sup>-A: a new, highly effective treatment for hairy cell leukemia. Kenilworth, New Jersey; 1986 Jul.</p><p>239. Castaigne S, Sigaux F, Cantell K et al. Interferon alpha in the treatment of hairy cell leukemia. <i>Cancer</i>. 1986; 57:1681-4. http://www.ncbi.nlm.nih.gov/pubmed/3948138?dopt=AbstractPlus</p><p>243. Holmes R, Whiteside MG, Schwarz MA et al. Treatment of hairy cell leukemia with increasing doses of recombinant alpha A interferon. <i>Aust N Z J Med</i>. 1988; 18:557-62. http://www.ncbi.nlm.nih.gov/pubmed/3196242?dopt=AbstractPlus</p><p>246. Worman CP, Catovsky D, Beavan PC et al. Interferon is effective in hairy-cell leukaemia. <i>Br J Haematol</i>. 1985; 60:759-63. http://www.ncbi.nlm.nih.gov/pubmed/3875366?dopt=AbstractPlus</p><p>248. Quesada JR, Hersh EM, Manning J et al. Treatment of hairy cell leukemia with recombinant α-interferon. <i>Blood</i>. 1986; 68:493-7. http://www.ncbi.nlm.nih.gov/pubmed/3730612?dopt=AbstractPlus</p><p>249. Quesada JR, Hersh EM, Reuben J et al. Treatment of hairy cell leukemia (HCL) with recombinant-DNA derived interferon alpha (RIFN(ALPHA)A). <i>Proc Am Soc Clin Oncol</i>. 1985; 4:222.</p><p>250. Ratain MJ, Golomb HM, Bardawil RG et al. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. <i>Blood</i>. 1987; 69:872-7. http://www.ncbi.nlm.nih.gov/pubmed/3814819?dopt=AbstractPlus</p><p>251. Cheson BD, Martin A. Clinical trials in hairy cell leukemia: current status and future directions. <i>Ann Intern Med</i>. 1987; 106:871-8. http://www.ncbi.nlm.nih.gov/pubmed/3555204?dopt=AbstractPlus</p><p>252. Ratain MJ, Golomb HM, Vardiman JW et al. Treatment of hairy cell leukemia with recombinant alpha<sub>2</sub> interferon. <i>Blood</i>. 1985; 65:644-8. http://www.ncbi.nlm.nih.gov/pubmed/3971043?dopt=AbstractPlus</p><p>253. Choudhury C, Raman C, Gallagher MT et al. Restoration of natural killer cell activity and immune competence against <i>Histoplasma capsulatum</i> in hairy-cell leukemia following treatment with recombinant alpha interferon. <i>Curr Ther Res</i>. 1989; 45:179-87.</p><p>254. Koeller JM. Biological response modifiers: the interferon alfa experience. <i>Am J Hosp Pharm</i>. 1989; 46(Suppl 2):S11-5. http://www.ncbi.nlm.nih.gov/pubmed/2481396?dopt=AbstractPlus</p><p>255. Borden EC. Progress toward therapeutic application of interferons, 1979-1983. <i>Cancer</i>. 1984; 54:2770-6. http://www.ncbi.nlm.nih.gov/pubmed/6208992?dopt=AbstractPlus</p><p>256. Stiehm ER, Kronenberg LH, Rosenblatt HM et al. Interferon: immunobiology and clinical significance. <i>Ann Intern Med</i>. 1982; 96:80-93. http://www.ncbi.nlm.nih.gov/pubmed/6172066?dopt=AbstractPlus</p><p>257. Craig JB. Biological response modifiers in the therapy of malignant disease: current status and future prospects. <i>Schumpert Med Q</i>. 1988; 7:88-107.</p><p>259. Goldstein D, Laszlo J, Rudnick S. Interferon therapy in cancer. In: Oldham RK, ed. Principles of cancer biotherapy. New York: Raven Press, Ltd. 1987:247-72.</p><p>260. Spiegel RJ. Intron<sup></sup> A (interferon alfa-2b): clinical overview and future directions. <i>Semin Oncol</i>. 1986; XIII(Suppl 2):89-101.</p><p>261. Goldstein D, Laszlo J. Interferon therapy in cancer: from imaginon to interferon. <i>Cancer Res</i>. 1986; 46:4315- 29. http://www.ncbi.nlm.nih.gov/pubmed/2425950?dopt=AbstractPlus</p><p>262. Lotze MT, Rosenberg SA. The immunologic treatment of cancer. <i>Ca Cancer J Clin</i>. 1988; 38:68-95. http://www.ncbi.nlm.nih.gov/pubmed/2450624?dopt=AbstractPlus</p><p>264. Brouty-Boye D, Wybier-Franqui J, Calvo C et al. Reversibility of the transformed and neoplastic phenotype: IV. Effects of long-term interferon treatment of C3H/10T½ cells transformed by methylcholanthrene and SV40 virus. <i>Int J Cancer</i>. 1984; 34:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6204950?dopt=AbstractPlus</p><p>265. World Health Organization. Progress in the development and use of antiviral drugs and interferon: report of a WHO scientific group. Geneva: World Health Organization; 1987.</p><p>266. Janssen JTP, de Pauw BE, Holdrinet RSG. Treatment of hairy-cell leukaemia with recombinant human α<sub>2</sub>- interferon. <i>Lancet</i>. 1984; 1:1025-6.</p><p>272. Spiegel RJ. Additional indications for interferon therapy: basal cell carcinoma, carcinoid, and chronic active hepatitis. <i>Semin Oncol</i>. 1988; 15(Suppl 5):41-5. http://www.ncbi.nlm.nih.gov/pubmed/3057643?dopt=AbstractPlus</p><p>278. Zorsky P, Siegel RS. Hairy-cell leukemia. <i>Drug Ther</i>. 1986; 16:137-9, 143.</p><p>282. Zoon K, Zur Nedden D, Arnheiter H. Specific binding of human α interferon to a high affinity cell surface binding site on bovine kidney cells. <i>J Biol Chem</i>. 1982; 257:4695-7. http://www.ncbi.nlm.nih.gov/pubmed/6175643?dopt=AbstractPlus</p><p>286. Smyth JF, Balkwill FR, Cavalli F et al. Interferons in oncology: current status and future directions. <i>Eur J Cancer Clin Oncol</i>. 1987; 23:887-9. http://www.ncbi.nlm.nih.gov/pubmed/2443361?dopt=AbstractPlus</p><p>299. Figlin RA. Biotherapy in clinical practice. <i>Semin Hematol</i>. 1989; 26(Suppl 3):15-24. http://www.ncbi.nlm.nih.gov/pubmed/2477904?dopt=AbstractPlus</p><p>300. Spiegel RJ. Clinical overview of alpha interferon: studies and future directions. <i>Cancer</i>. 1987; 59:626-31. http://www.ncbi.nlm.nih.gov/pubmed/3542185?dopt=AbstractPlus</p><p>301. Talpaz M, Kantarjian H, McCredie K et al. Therapy of chronic myelogenous leukemia. <i>Cancer</i>. 1987; 59:664-7. http://www.ncbi.nlm.nih.gov/pubmed/10822467?dopt=AbstractPlus</p><p>302. Fahey JL, Sarna G, Gale RP et al. Immune interventions in disease. <i>Ann Intern Med</i>. 1987; 106:257-74. http://www.ncbi.nlm.nih.gov/pubmed/2432815?dopt=AbstractPlus</p><p>303. Bergsagel DE, Haas RH, Messner HA. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. <i>Semin Oncol</i>. 1986; XIII(Suppl 2):29-34.</p><p>305. Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. <i>Am J Med</i>. 1986; 81:871-82. http://www.ncbi.nlm.nih.gov/pubmed/3535496?dopt=AbstractPlus</p><p>306. Fauci AS, Rosenberg SA, Sherwin SA et al. Immunomodulators in clinical medicine. <i>Ann Intern Med</i>. 1987; 106:421-33. http://www.ncbi.nlm.nih.gov/pubmed/2433978?dopt=AbstractPlus</p><p>307. Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha<sub>A</sub> in chronic myelogenous leukemia. <i>N Engl J Med</i>. 1986; 314:1065-9. http://www.ncbi.nlm.nih.gov/pubmed/3457264?dopt=AbstractPlus</p><p>308. Opalka B, Kloke O, Bartram CR et al. Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. <i>Lancet</i>. 1989; 1:1334. http://www.ncbi.nlm.nih.gov/pubmed/2566865?dopt=AbstractPlus</p><p>309. Talpaz M. Activity of alpha-interferons in chronic myelogenous leukaemia. <i>Br J Clin Pract</i>. 1988; 42(Suppl 62):13-5.</p><p>310. Ozer H. Biotherapy of chronic myelogenous leukemia with interferon. <i>Semin Oncol</i>. 1988; 15(Suppl 5):14-20. http://www.ncbi.nlm.nih.gov/pubmed/2461592?dopt=AbstractPlus</p><p>311. Ozer H, Mick R, Testa J et al. Subcutaneous alpha- interferon (AIFN) shows substantial activity in untreated chronic phase Philadelphia chromosome positive (ph+) chronic myelogenous leukemia (CML). <i>Proc Am Soc Clin Oncol</i>. 1988; 7:A684.</p><p>312. Talpaz M, Kantarjian HM, Kurzrock R et al. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. <i>Semin Hematol</i>. 1988; 25:62-73. http://www.ncbi.nlm.nih.gov/pubmed/2450402?dopt=AbstractPlus</p><p>331. Krown SE. Therapeutic options in renal-cell carcinoma. <i>Semin Oncol</i>. 1985; 12(Suppl 5):13-7. http://www.ncbi.nlm.nih.gov/pubmed/2417331?dopt=AbstractPlus</p><p>332. Sarna G, Figlin R, De Kernion J. Interferon in renal cell carcinoma. <i>Cancer</i>. 1987; 59:610-2. http://www.ncbi.nlm.nih.gov/pubmed/3542184?dopt=AbstractPlus</p><p>333. Quesada JR. Biologic response modifiers in the therapy of metastatic renal cell carcinoma. <i>Semin Oncol</i>. 1988; 15:396-407. http://www.ncbi.nlm.nih.gov/pubmed/2457256?dopt=AbstractPlus</p><p>336. Grosh WW. Renal cell carcinoma: treatment with interferon. <i>Compr Ther</i>. 1987; 13:34-9. http://www.ncbi.nlm.nih.gov/pubmed/2438082?dopt=AbstractPlus</p><p>339. Creagan ET, Ahmann DL, Frytak S et al. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma: updated analyses. <i>Cancer</i>. 1987; 59:638-46. http://www.ncbi.nlm.nih.gov/pubmed/10822463?dopt=AbstractPlus</p><p>341. Steis RG, Foon KA, Longo DL. Current and future uses of recombinant interferon alpha in the treatment of low-grade non- Hodgkin’s lymphoma. <i>Cancer</i>. 1987; 59:658-63. http://www.ncbi.nlm.nih.gov/pubmed/10822466?dopt=AbstractPlus</p><p>342. Kaplan EH, Rosen ST, Norris DB et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T- cell lymphoma. <i>J Natl Cancer Inst</i>. 1990; 82:208-12. http://www.ncbi.nlm.nih.gov/pubmed/2104937?dopt=AbstractPlus</p><p>348. Foon KA, Roth MS, Bunn PA Jr. Interferon therapy of non-Hodgkin’s lymphoma. <i>Cancer</i>. 1987; 59:601-4. http://www.ncbi.nlm.nih.gov/pubmed/3492259?dopt=AbstractPlus</p><p>349. Merck Sharp &amp; Dohme Corporation. Rebetol<sup></sup> (ribavirin) capsules and oral solution prescribing information. Whitehouse Station, NJ; 2013 Nov.</p><p>351. Belldegrun AS, Franklin JR, O’Donnell MA et al. Superficial bladder cancer: the role of interferon-α. <i>J Urol</i>. 1998; 159:1793-801. http://www.ncbi.nlm.nih.gov/pubmed/9598463?dopt=AbstractPlus</p><p>356. Torti FM, Shortliffe LD, Williams RD et al. Alpha- interferon in superficial bladder cancer: a Northern California Oncology Group study. <i>J Clin Oncol</i>. 1988; 6:476-83. http://www.ncbi.nlm.nih.gov/pubmed/3280742?dopt=AbstractPlus</p><p>358. Berek JS, Markman M, Blessing JA et al. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. <i>Gynecol Oncol</i>. 1999; 74:48-52. http://www.ncbi.nlm.nih.gov/pubmed/10385550?dopt=AbstractPlus</p><p>359. Berek JS, Markman M, Stonebraker B et al. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. <i>Gynecol Oncol</i>. 1999; 75:10-4. http://www.ncbi.nlm.nih.gov/pubmed/10502418?dopt=AbstractPlus</p><p>360. Berek JS, Hacker NF, Lichtenstein A et al. Intraperitoneal recombinant alpha-interferon for ′salvage′ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. <i>Cancer Res</i>. 1985; 45:4447-53. http://www.ncbi.nlm.nih.gov/pubmed/4028027?dopt=AbstractPlus</p><p>374. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. <i>J Clin Oncol</i>. 1984; 2:336-52. http://www.ncbi.nlm.nih.gov/pubmed/6323641?dopt=AbstractPlus</p><p>376. Quesada JR, Talpaz M, Rios A et al. Clinical toxicity of interferons in cancer patients: a review. <i>J Clin Oncol</i>. 1986; 4:234-43. http://www.ncbi.nlm.nih.gov/pubmed/2418169?dopt=AbstractPlus</p><p>378. Groopman JE. Biology and therapy of epidemic Kaposi’s sarcoma. <i>Cancer</i>. 1987; 59:633-7. http://www.ncbi.nlm.nih.gov/pubmed/10822462?dopt=AbstractPlus</p><p>381. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome—related Kaposi’s sarcoma. <i>Semin Oncol</i>. 1985; 12:2-6. http://www.ncbi.nlm.nih.gov/pubmed/3909416?dopt=AbstractPlus</p><p>383. Mitsuyasu RT, Taylor JMG, Glaspy J et al. Heterogeneity of epidemic Kaposi’s sarcoma: implications for therapy. <i>Cancer</i>. 1986; 57:1657-61. http://www.ncbi.nlm.nih.gov/pubmed/3081246?dopt=AbstractPlus</p><p>384. Taylor J, Afrasiabi R, Fahey JL et al. Prognostically significant classification of immune changes in AIDS with Kaposi’s sarcoma. <i>Blood</i>. 1986; 67:666-71. http://www.ncbi.nlm.nih.gov/pubmed/3081065?dopt=AbstractPlus</p><p>385. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. <i>Semin Oncol</i>. 1986; XIII(Suppl 2):43-7.</p><p>386. Krown SE. The role of interferon in the therapy of epidemic Kaposi’s sarcoma. <i>Semin Oncol</i>. 1987; 14(Suppl 3):27-33. http://www.ncbi.nlm.nih.gov/pubmed/2440110?dopt=AbstractPlus</p><p>387. Fahey JL, Taylor J, Afrasiabi R et al. AIDS and Kaposi sarcoma. In: Reif AE, Mitchell MS, eds. Immunity to cancer. New York: Academic Press; 1985:347-61.</p><p>388. Mitsuyasu R, Afrasiabi R, Taylor J et al. Immunologic prognostic variable in patients with AIDS and Kaposi’s sarcoma (KS). <i>Proc Am Soc Clin Oncol</i>. 1985; 4:1.</p><p>389. Mitsuyasu RT, Afrasiabi R, Taylor J et al. Prognostic immunologic variables in epidemic Kaposi’s sarcoma (KS). International conference on acquired immunodeficiency syndrome (AIDS). Atlanta, GA: 1985 April 14-17. Abstract.</p><p>394. Krown SE, Gold JW, Real FX et al. Interferon alpha-2A +/− vinblastine (VLB) in AIDS-associated Kaposi’s sarcoma (KS/AIDS): therapeutic activity, toxicity and effects on HTLV-III/LAV viremia. <i>J Interferon Res</i>. 1986; 6(Suppl 1):3.</p><p>398. Krown SE, Bundow B, Gansbacher W et al. Interferon-α (IFN-α) plus zidovudine (ZDV) in AIDS-associated Kaposi’s sarcoma (AIDS/KS): an ongoing phase I trial. <i>Proc Am Soc Clin Oncol</i>. 1988; 7:1.</p><p>402. Bocci V, Mogensen KE, Muscettola M et al. Degradation of human<sup>125</sup>I-interferon alpha by isolated perfused rabbit kidney and liver. <i>J Lab Clin Med</i>. 1983; 101:857- 63. http://www.ncbi.nlm.nih.gov/pubmed/6854125?dopt=AbstractPlus</p><p>403. Kadmon Pharmaceuticals, LLC. Ribasphere<sup></sup> (ribavirin) capsules prescribing information. Warrendale, PA; 2012 Dec.</p><p>409. Bornemann LD, Spiegel HE, Dziewanowska ZE et al. Intravenous and intramuscular pharmacokinetics of recombinant leukoctye A interferon. <i>Eur J Clin Pharmacol</i>. 1985; 28:469-71. http://www.ncbi.nlm.nih.gov/pubmed/4029251?dopt=AbstractPlus</p><p>413. Priestman TJ. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. <i>Lancet</i>. 1980; 2:113-8. http://www.ncbi.nlm.nih.gov/pubmed/6157064?dopt=AbstractPlus</p><p>414. Habif DV, Lipton R, Cantell K. Interferon crosses blood-cerebrospinal fluid barrier in monkeys (38790). <i>Proc Soc Exp Biol Med</i>. 1975; 149:287-9. http://www.ncbi.nlm.nih.gov/pubmed/1144440?dopt=AbstractPlus</p><p>421. Collins JM, Riccardi R, Trown P et al. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. <i>Cancer Drug Delivery</i>. 1985; 2:247-53. http://www.ncbi.nlm.nih.gov/pubmed/4063949?dopt=AbstractPlus</p><p>434. Rohatiner AZS, Balkwill FR, Griffin DB et al. A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. <i>Cancer Chemother Pharmacol</i>. 1982; 9:97-102. http://www.ncbi.nlm.nih.gov/pubmed/7172412?dopt=AbstractPlus</p><p>436. Wills RJ, Smith RA. Pharmacokinetics of interferons. In: Smith RA, ed. Interferon treatment of neurologic disorders. New York: Marcel Dekker; 1988:103-33.</p><p>439. Hairy cell leukemia treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>440. Kaposi Sarcoma Treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>441. Chronic myelogenous leukemia treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>442. Adult non-Hodgkin lymphoma treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>443. Renal cell cancer treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>444. Bocci V, Pacini A, Muscettola M et al. Renal filtration, absorption, and catabolism of human alpha interferon. <i>J Interferon Res</i>. 1981; 1:347-52. http://www.ncbi.nlm.nih.gov/pubmed/6180066?dopt=AbstractPlus</p><p>446. Bino T, Edery H, Gertler A et al. Involvement of the kidney in catabolism of human leukocyte interferon. <i>J Gen Virol</i>. 1982; 59:39-45. http://www.ncbi.nlm.nih.gov/pubmed/6175730?dopt=AbstractPlus</p><p>447. Bino T, Madar Z, Gertler A et al. The kidney is the main site of interferon degradation. <i>J Interferon Res</i>. 1982; 2:301-8. http://www.ncbi.nlm.nih.gov/pubmed/7119510?dopt=AbstractPlus</p><p>448. Bladder cancer treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>449. Ovarian epithelial cancer treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>450. Melanoma treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute. Accessed 2012 Nov 14.</p><p>456. WHO Expert Committee on Biological Standardization. Requirements for human interferons prepared from lymphoblastoid cells. Geneva: World Health Organization, Technical Report Series, no. 786; 1989:72-93.</p><p>459. Groopman JE, Broder S. Cancer in AIDS and other immunodeficiency states. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer—principles and practice of oncology. Philadelphia: Lippincott; 1988:1964-5.</p><p>461. Scott GM. The toxic effects of interferon in man. In: Gresser I, ed. Interferon 5. London and New York: Academic Press; 1983:87-99.</p><p>465. Oldham RR. Toxic effects of interferon. <i>Science</i>. 1983; 219:902. http://www.ncbi.nlm.nih.gov/pubmed/6186027?dopt=AbstractPlus</p><p>469. Deyton LR, Walker RE, Kovacs JA et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi’s sarcoma. <i>N Engl J Med</i>. 1989; 321:1246-9. http://www.ncbi.nlm.nih.gov/pubmed/2638573?dopt=AbstractPlus</p><p>470. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha<sub>2</sub> interferon-related cardiomyopathy. <i>Am J Med</i>. 1988; 85:549-51. http://www.ncbi.nlm.nih.gov/pubmed/3177405?dopt=AbstractPlus</p><p>471. Sarna G, Figlin R, Callaghan M. α (human leukocyte) interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. <i>J Biol Response Mod</i>. 1983; 2:343-7. http://www.ncbi.nlm.nih.gov/pubmed/6315898?dopt=AbstractPlus</p><p>472. Budd GT, Bukowski RM, Miketo L et al. Phase-I trial of ultrapureTM human leukocyte interferon in human malignancy. <i>Cancer Chemother Pharmacol</i>. 1984; 12:39-42. http://www.ncbi.nlm.nih.gov/pubmed/6690072?dopt=AbstractPlus</p><p>473. Grunberg SM, Kempf RA, Itri LM et al. Phase II study of recombinant alpha interferon in the treatment of advanced non- small cell carcinoma lung. <i>Cancer Treat Rep</i>. 1985; 69:1031-2. http://www.ncbi.nlm.nih.gov/pubmed/4028036?dopt=AbstractPlus</p><p>474. Cooper MR, Fefer A, Thompson J et al. Alpha-2- interferon/melphalan/prednisone in previously treated patients with multiple myeloma: a phase I-II trial. <i>Cancer Treat Rep</i>. 1986; 70:473-6. http://www.ncbi.nlm.nih.gov/pubmed/3698041?dopt=AbstractPlus</p><p>475. Martino S, Ratanatharathorn V, Karanes C et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. <i>J Cancer Res Clin Oncol</i>. 1987; 113:376-8. http://www.ncbi.nlm.nih.gov/pubmed/3597523?dopt=AbstractPlus</p><p>487. Gastineau DA, Habermann TM, Hermann RC. Severe neuropathy associated with low-dose recombinant interferon-alpha. <i>Am J Med</i>. 1989; 87:116. http://www.ncbi.nlm.nih.gov/pubmed/2741970?dopt=AbstractPlus</p><p>490. AUSTIMS Research Group. Interferon-α and transfer factor in the treatment of multiple sclerosis: a double-blind placebo-controlled trial. <i>J Neurol Neurosurg Psychiatry</i>. 1989; 52:566-74. http://www.ncbi.nlm.nih.gov/pubmed/2659737?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1032161&amp;blobtype=pdf</p><p>507. Burman P, , Oberg K et al. Autoimmune thyroid disease in interferon treated patients. <i>Lancet</i>. 1985; 2:100-1. http://www.ncbi.nlm.nih.gov/pubmed/2861513?dopt=AbstractPlus</p><p>508. Fentiman IS, Balkwill FR, Thomas BS et al. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. <i>Eur J Cancer Clin Oncol</i>. 1988; 24:1299-303. http://www.ncbi.nlm.nih.gov/pubmed/2460358?dopt=AbstractPlus</p><p>509. Schultz M, Muller R, Von Zur Muhlen A et al. Induction of hyperthyroidism by interferon-α-2b. <i>Lancet</i>. 1989; 1:1452. http://www.ncbi.nlm.nih.gov/pubmed/2567459?dopt=AbstractPlus</p><p>510. Fentiman IS, Thomas BS, Balkwill FR et al. Primary hypothyroidism associated with interferon therapy of breast cancer. <i>Lancet</i>. 1985; 1:1166. http://www.ncbi.nlm.nih.gov/pubmed/2860373?dopt=AbstractPlus</p><p>522. Cottler-Fox M, Torrisi J, Sptizer TR et al. Increased toxicity of total body irradiation in patients receiving interferon for leukaemia. <i>Lancet</i>. 1990; 335:174.</p><p>523. Real FX, Krown SE, Nisce LZ et al. Unexpected toxicity from radiation therapy in two patients with Kaposi’s sarcoma receiving interferon. <i>J Biol Response Mod</i>. 1985; 4:141-6. http://www.ncbi.nlm.nih.gov/pubmed/3998765?dopt=AbstractPlus</p><p>533. Higashi Y, Sokawa Y. Microinjection of interferon and 2′,5′-oligoadenylate into mouse L cells and their effects on virus growth. <i>J Biochem</i>. 1982; 91:2021-8. http://www.ncbi.nlm.nih.gov/pubmed/6181054?dopt=AbstractPlus</p><p>534. Vengris VE, Stollar BD, Pitha PM. Interferon externalization by producing cell before induction of antiviral state. <i>Virology</i>. 1975; 65:410-7. http://www.ncbi.nlm.nih.gov/pubmed/165620?dopt=AbstractPlus</p><p>648. Giacomini P, Aguzzi A, Pestka S et al. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor- associated antigens by human melanoma cells. <i>J Immunol</i>. 1984; 133:1649-55. http://www.ncbi.nlm.nih.gov/pubmed/6747299?dopt=AbstractPlus</p><p>714. Masucci MG, Szigeti R, Klein E et al. Effect of interferon-β<sub>1</sub> from E. coli on some cell functions. <i>Science</i>. 1980; 209: 1431-35. http://www.ncbi.nlm.nih.gov/pubmed/6158096?dopt=AbstractPlus</p><p>715. Foon K, Doroshow J, Bonnem E et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. <i>J Biol Response Mod</i>. 1988; 7:540-5. http://www.ncbi.nlm.nih.gov/pubmed/3145964?dopt=AbstractPlus</p><p>717. Herberman RB, Djeu JY, Ortaldo JR et al. Role of interferon in the augmentation of natural and antibody-dependent cell-mediated cytotoxicity. <i>Cancer Treat Rep</i>. 1978; 62:1893-96. http://www.ncbi.nlm.nih.gov/pubmed/728907?dopt=AbstractPlus</p><p>719. Heron I, Hoakland M, Moller-Larsen A et al. The effect of interferon on lymphocyte-mediated effector cell functions: selective enhancement of natural killer cells. <i>Cell Immunol</i>. 1979; 42:183-7. http://www.ncbi.nlm.nih.gov/pubmed/155499?dopt=AbstractPlus</p><p>740. Fellous M, Kamoun M, Gresser I et al. Enhanced expression of HLA antigens and beta 2-microglobulin on interferon-treated human lymphoid cells. <i>Eur J Immunol</i>. 1979; 9:446-52. http://www.ncbi.nlm.nih.gov/pubmed/91516?dopt=AbstractPlus</p><p>863. Krown SE, Mintzer D, Cunningham-Rundles S et al. High- dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. <i>Cancer Treat Rep</i>. 1987; 71:39-45. http://www.ncbi.nlm.nih.gov/pubmed/3791267?dopt=AbstractPlus</p><p>906. Whitaker-Dowling P, Younger JS. Antiviral effects of interferons in different virus-host cell systems. In: Pfeffer LM, ed. Mechanisms of interferon actions. CRC Press: Boca Raton FL; 1987:83-98.</p><p>931. Rios A, Mansell P, Newell G et al. The use of lymphoblastoid interferon (HuIFNα[Ly]) and vinblastine in the treatment of acquired immunodeficiency syndrome (AIDS) related Kaposi’s Sarcoma (KS). <i>Proc Am Soc Clin Oncol</i>. 1985; 4:6.</p><p>932. Figlin RA, deKernlon JB, Maldazys J et al. Treatment of renal cell carcinoma with α(human leukocyte) interferon and vinblastine in combination: a phase I-II trial. <i>Cancer Treat Rep</i>. 1985; 69:263-7. http://www.ncbi.nlm.nih.gov/pubmed/3978656?dopt=AbstractPlus</p><p>935. Swanson DA, Quesada JR. Interferon therapy for metastatic renal cell carcinoma. <i>Semin Surg Oncol</i>. 1988; 4:174-7. http://www.ncbi.nlm.nih.gov/pubmed/3142007?dopt=AbstractPlus</p><p>936. Krown SE. Clinical trials of interferons in human malignancy. In: Pfeffer L. Mechanisms of interferons’ actions. Boca Raton, FL; CRC Press; 1987:143-78.</p><p>937. Torrisi J, Berg C, Bonnem E et al. The combined use of interferon and radiotherapy in cancer management. <i>Semin Oncol</i>. 1986; 13(Suppl 2):78-83. http://www.ncbi.nlm.nih.gov/pubmed/3764443?dopt=AbstractPlus</p><p>938. Torrisi J, Berg C, Harter K et al. Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy. <i>Int J Radiat Oncol Biol Phys</i>. 1986; 12:1453-6. http://www.ncbi.nlm.nih.gov/pubmed/3759573?dopt=AbstractPlus</p><p>939. Mattson LR, Holsti A, Niiranen L et al. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. <i>J Biol Response Mod</i>. 1985; 4:8-17. http://www.ncbi.nlm.nih.gov/pubmed/2984340?dopt=AbstractPlus</p><p>950. Levine M, Jones M. Interferon and drug metabolism. <i>Clin Pharm</i>. 1983; 2:210-1. http://www.ncbi.nlm.nih.gov/pubmed/6192966?dopt=AbstractPlus</p><p>951. Bauman JH, Fuentes RJ. Interferon and drug metabolism. <i>Clinical Pharmacy</i>. 1983; 2:211.</p><p>952. el Azhary R, Renton KW, Mannering GJ. Effect of interferon inducing agents (polyriboinosinic acid- polyribocytidylic acid and tilorone) on the heme turnover of hepatic cytochrome P-450. <i>Mol Pharmacol</i>. 1980; 17:395-9. http://www.ncbi.nlm.nih.gov/pubmed/7393215?dopt=AbstractPlus</p><p>953. Parkinson A, Lasker J, Kramer MJ et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. <i>Drug Metab Dispos</i>. 1982; 10:579-85. http://www.ncbi.nlm.nih.gov/pubmed/6130903?dopt=AbstractPlus</p><p>954. Singh G, Renton KW, Stebbing N. Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation. <i>Biochem Biophys Res Commun</i>. 1982; 106:1256-61. http://www.ncbi.nlm.nih.gov/pubmed/6180750?dopt=AbstractPlus</p><p>955. Weissmann C, Nagata S, Boll W et al. Structure and expression of human IFN-alpha genes. <i>Philos Trans R Soc Lond B</i>. 1982; 299:7-28.</p><p>962. Hartshorn KL, Vogt MW, Chou TC et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. <i>Antimicrob Agents Chemother</i>. 1987; 31:168-72. http://www.ncbi.nlm.nih.gov/pubmed/3471180?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=174685&amp;blobtype=pdf</p><p>963. Dickson D. Death halts interferon trials in France. <i>Science</i>. 1982; 218:772. http://www.ncbi.nlm.nih.gov/pubmed/6182613?dopt=AbstractPlus</p><p>964. Sherwin SA, Mayer D, Ochs JJ et al. Recombinant leukocyte A interferon in advanced breast cancer: results of a phase II efficacy trial. <i>Ann Intern Med</i>. 1983; 98:598- 602. http://www.ncbi.nlm.nih.gov/pubmed/6342490?dopt=AbstractPlus</p><p>975. Schafer TW, Lieberman M, Cohen M et al. Interferon administered orally: protection of neonatal mice from lethal virus challenge. <i>Science</i>. 1972; 176:1326-7. http://www.ncbi.nlm.nih.gov/pubmed/4338344?dopt=AbstractPlus</p><p>983. Arvin AM, Schmidt NJ, Cnatell K et al. Alpha interferon administration to infants with congenital rubella. <i>Antimicrob Agents Chemother</i>. 1982; 21:259-61. http://www.ncbi.nlm.nih.gov/pubmed/6176183?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=181869&amp;blobtype=pdf</p><p>984. Bocci V, Russi-Sorce M, Cirri G et al. Role of liver in the inactivation of interferon. <i>Proc Soc Exp Biol Med</i>. 1968; 129:62-5. http://www.ncbi.nlm.nih.gov/pubmed/4176732?dopt=AbstractPlus</p><p>989. Arnheiter H, Ohno M, Smith M et al. Orientation of a human leukocyte interferon molecule on ints cell surface receptor: carboxyl terminus remains accessible to a monoclonal antibody made against a synthetic interferon fragment. <i>Proc Natl Acad Sci USA</i>. 1983; 80:2539-43. http://www.ncbi.nlm.nih.gov/pubmed/6302694?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=393861&amp;blobtype=pdf</p><p>996. Kovach JS, Svingen PA. Enhancement of the antiproliferative activity of human interferon by polyamine depletion. <i>Cancer Treat Rep</i>. 1985; 69:97-103. http://www.ncbi.nlm.nih.gov/pubmed/3917854?dopt=AbstractPlus</p><p>1029. Ozer H, Dear K, Testa J et al. Prolonged administration of subcutaneous alpha-interferon induces major clinical and complete cytogenetic remissions in untreated Philadelphia chromosome positive (PH+) chronic myelogenous leukemia (CML). <i>Proc Am Soc Clin Oncol</i>. 1990; 9:A783.</p><p>1042. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. <i>Cancer Res</i>. 1990; 50:3473-86. http://www.ncbi.nlm.nih.gov/pubmed/1692761?dopt=AbstractPlus</p><p>1051. Krown SE, Gold JWM, Niedzwiecki D et al. Interferon- α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). <i>Ann Intern Med</i>. 1990; 112:812-21. http://www.ncbi.nlm.nih.gov/pubmed/1971504?dopt=AbstractPlus</p><p>1108. von Wussow P, Block B, Hartmann F et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. <i>Cancer</i>. 1988; 61:1071-4. http://www.ncbi.nlm.nih.gov/pubmed/3342367?dopt=AbstractPlus</p><p>1109. Papa G, Vegna ML, Defazio D et al. Recombinant interferon alfa-2A in untreated cutaneous T-cell lymphomas. <i>J Interferon Res</i>. 1989; 9(Suppl 2):S112.</p><p>1110. Covelli A, Papa G, Vegna ML et al. Recombinant alpha- 2A interferon (IFN) as initial therapy in mycosis fungoides (MF): results of a 3-year follow-up. <i>Proc Am Soc Clin Oncol</i>. 1989; 8:A978.</p><p>1111. Edelson RL. Treatment of cutaneous T cell lymphoma. In: van Vloten WA, Willemze R, Lange Vejlsgaard G et al, eds. Current Problems in Dermatology. Basel: Karger; 1990:226-37.</p><p>1117. Thestrup-Pedersen K, Hammer R, Kaltoft K et al. Treatment of mycosis fungoides with recombinant interferon- α2a<sup>2</sup> alone and in combination with etretinate. <i>Br J Dermatol</i>. 1988; 118:811-8. http://www.ncbi.nlm.nih.gov/pubmed/3042011?dopt=AbstractPlus</p><p>1118. Gilewski TA, Richards JM. Biologic response modifiers in Non-Hodgkin’s lymphomas. <i>Semin Oncol</i>. 1990; 17:74-87. http://www.ncbi.nlm.nih.gov/pubmed/1689508?dopt=AbstractPlus</p><p>1143. Gilewski TA, Golomb HM. Design of combination biotherapy studies: future goals and challenges. <i>Semin Oncol</i>. 1990; 17(Suppl 1):3-10. http://www.ncbi.nlm.nih.gov/pubmed/1689077?dopt=AbstractPlus</p><p>1152. Glaspy JA, Jacobs AD, Golde DW. Evolving therapy of hairy cell leukemia. <i>Cancer</i>. 1987; 59:652-7. http://www.ncbi.nlm.nih.gov/pubmed/10822465?dopt=AbstractPlus</p><p>1153. Thompson JA, Fefer A. Evolving therapy of hairy cell leukemia. <i>Cancer</i>. 1987; 652-7. (IDIS 225547)</p><p>1159. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alcaloids and other chemotherapeutic agents against human tumors in clonogenic assay. <i>Cancer Chemother Pharmacol</i>. 1983; 10:161-6. http://www.ncbi.nlm.nih.gov/pubmed/6861260?dopt=AbstractPlus</p><p>1174. Mihich E. Biological response modifiers: their potential and limitations in cancer therapeutics. <i>Cancer Invest</i>. 1985; 3:71-83. http://www.ncbi.nlm.nih.gov/pubmed/2578860?dopt=AbstractPlus</p><p>1175. Mihich E. Future perspectives for biological response modifiers: a viewpoint. <i>Semin Oncol</i>. 1986: 13:234-54.</p><p>1176. Oldham RK. Biologicals and biological response modifiers: fourth modality of cancer treatment. <i>Cancer Treat Rep</i>. 1984; 68:221-32. http://www.ncbi.nlm.nih.gov/pubmed/6198081?dopt=AbstractPlus</p><p>1177. Huez G, Silhol M, Lebleu B. Microinjected interferon does not promote an antiviral response in HeLa cells. <i>Biochem Biophys Res Commun</i>. 1983; 110:155-60. http://www.ncbi.nlm.nih.gov/pubmed/6301439?dopt=AbstractPlus</p><p>1190. Branca AA, Baglioni C. Evidence that types I and II interferons have different receptors. <i>Nature</i>. 1981; 294:768-70. http://www.ncbi.nlm.nih.gov/pubmed/6172715?dopt=AbstractPlus</p><p>1197. Anderson P, Yip YK, Vilcek J. Specific binding of<sup>125</sup>I-human interferon-gamma to high affinity receptors on human fibroblasts. <i>J Biol Chem</i>. 1982; 257:11301-4. http://www.ncbi.nlm.nih.gov/pubmed/6288678?dopt=AbstractPlus</p><p>1211. Gresser I, Bourali C, Levy JP et al. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. <i>Proc Natl Acad Sci USA</i>. 1969; 63:51-7. http://www.ncbi.nlm.nih.gov/pubmed/5257966?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=534033&amp;blobtype=pdf</p><p>1240. Delage R, Ritz J, Anderson KC. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. <i>Hematol Oncol Clin North Am</i>. 1990; 4:369-88. http://www.ncbi.nlm.nih.gov/pubmed/2182597?dopt=AbstractPlus</p><p>1241. Gresser I, Maury C, Woodrow D et al. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. <i>Int J Cancer</i>. 1988; 41:135-42. http://www.ncbi.nlm.nih.gov/pubmed/3422071?dopt=AbstractPlus</p><p>1339. Langer JA, Pestka S. Structure of interferons. <i>Pharmacol Ther</i>. 1985; 27:371-401. http://www.ncbi.nlm.nih.gov/pubmed/2413490?dopt=AbstractPlus</p><p>1340. Lane HC, Deyton LR. Interferon alfa-induced cardiac dysfunction. <i>N Engl J Med</i>. 1990; 322:1469.</p><p>1342. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. <i>J Clin Oncol</i>. 1999; 17:968-75. http://www.ncbi.nlm.nih.gov/pubmed/10071291?dopt=AbstractPlus</p><p>1343. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. <i>J Clin Oncol</i>. 1998; 16:1743-51. http://www.ncbi.nlm.nih.gov/pubmed/9586887?dopt=AbstractPlus</p><p>1344. Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. <i>Br J Cancer</i>. 1998; 77:1280-6. http://www.ncbi.nlm.nih.gov/pubmed/9579834?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2150174&amp;blobtype=pdf</p><p>1345. Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. <i>Ann Oncol</i>. 1996; 7:827-35. http://www.ncbi.nlm.nih.gov/pubmed/8922197?dopt=AbstractPlus</p><p>1346. Legha SS, Ring S, Eton O et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. <i>J Clin Oncol</i>. 1998; 16:1752-9. http://www.ncbi.nlm.nih.gov/pubmed/9586888?dopt=AbstractPlus</p><p>1347. Atkins MB, Flaherty LE, Sosman JA, principal investigators. Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999). Protocol ID: E-E3695. From CancerNet: PDQ Clinical Trials (database). Bethesda, MD: National Cancer Institute; accessed 1999 Nov 29.</p><p>1361. Pichert G, Jost LM, Zobeli L et al. Thyroiditis after treatment with interleukin-2 and interferon alfa-2a. <i>Br J Cancer</i>. 1990; 62:100-4. http://www.ncbi.nlm.nih.gov/pubmed/2390468?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1971759&amp;blobtype=pdf</p><p>1362. Conlon KC, Urba WJ, Smith JW et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha- interferon therapy. <i>Cancer</i>. 1990; 65:2237-42. http://www.ncbi.nlm.nih.gov/pubmed/2346907?dopt=AbstractPlus</p><p>1382. Bunn PA Jr, Fuks Z. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer—principles and practice of oncology. Philadelphia: Lippincott; 1989:1799-1808.</p><p>1385. Simoni R, Cavalieri R, Coppola G et al. Recombinant leukocyte interferon alfa-2A in the treatment of mycosis fungoides. <i>J Biol Regul Homeost Agents</i>. 1987; 1:93-9. http://www.ncbi.nlm.nih.gov/pubmed/3504088?dopt=AbstractPlus</p><p>1420. Kantarjian HM, Talpaz M, Kurzrock R et al. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. <i>Acta Haematol (Basel)</i>. 1987; 78(Suppl 1):70-4.</p><p>1426. O’Brien WJ, Coe EC, Taylor JL. Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir, a possible mechanism of synergistc antiviral activity. <i>Antimicrob Agents Chemother</i>. 1990; 34:1178-82. http://www.ncbi.nlm.nih.gov/pubmed/2393279?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=171780&amp;blobtype=pdf</p><p>1434. Chirigos MA, Pearson JW. Cure of murine leukemia with drug and interferon treatment. <i>J Natl Cancer Inst</i>. 1973; 51:1367-8. http://www.ncbi.nlm.nih.gov/pubmed/4745868?dopt=AbstractPlus</p><p>1435. Smyth JF, Balkwill FR, Fergusson RJ. Interferons combined with other anti-cancer agents—studies in experimental systems. In: Smyth JF, ed. European School of Oncology Monographs. New York: Springer; 1987;39-42.</p><p>1436. Wolf LM, Leitzel KE, Pegg AE et al. The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines. <i>J Biol Response Mod</i>. 1985; 4:391-5. http://www.ncbi.nlm.nih.gov/pubmed/3928826?dopt=AbstractPlus</p><p>1437. Kyriakidis DA, Kortsaris A. Effects of human interferon and alpha-difluoromethylornithine on T47D cells. <i>J Interferon Res</i>. 1986; 6:527-33. http://www.ncbi.nlm.nih.gov/pubmed/2433364?dopt=AbstractPlus</p><p>1438. Bregman MD, Meyskens FL Jr. Alpha- difluoromethylornithine and either dexamethasone, interferon, putrescine, retinoic acid, and sodium butyrate cooperatively modulate the growth of melanoma. First International Conference on Skin Melanoma. 1985: abstract 220.</p><p>1439. Bregman MD, Meyskens FL Jr. Difluoromethylornithine (DFMO) enhances inhibition of melanoma cell growth in soft agar by dexamethasone(DEX), clone A interferon(IFN), and trans retinoic acid(RA): a new approach to biological modification. <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1985; 26:326.</p><p>1440. Heston WD, Fleischmann J, Tackett RE et al. Effects of alph-difluorodimethyl ornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. <i>Cancer Res</i>. 1984; 44:3220-5. http://www.ncbi.nlm.nih.gov/pubmed/6430546?dopt=AbstractPlus</p><p>1443. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. <i>J Clin Oncol</i>. 1994; 12:806-11. http://www.ncbi.nlm.nih.gov/pubmed/8151323?dopt=AbstractPlus</p><p>1444. Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. <i>Melanoma Res</i>. 1993; 3:133-8. http://www.ncbi.nlm.nih.gov/pubmed/8518552?dopt=AbstractPlus</p><p>1445. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. <i>J Clin Oncol</i>. 1991; 9:1403-8. http://www.ncbi.nlm.nih.gov/pubmed/2072144?dopt=AbstractPlus</p><p>1446. Oncologic Drugs Advisory Committee Meeting. 55th meeting. Bethesda, MD: Food and Drug Administration; 1997 Dec 19.</p><p>1461. Douglas RG Jr. Antimicrobial agents [[continued]]: antiviral agents. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:1189-91,1193-1201.</p><p>1463. Mogensen KE, Bandu MT, Vignaux F et al. Binding of [<sup>125</sup>I] labelled human alpha interferon to human lymphoid cells. <i>Int J Cancer</i>. 1981; 28:575-82. http://www.ncbi.nlm.nih.gov/pubmed/6171531?dopt=AbstractPlus</p><p>1464. Pestka S, Langer JA, Zoon KC et al. Interferons and their actions. <i>Annu Rev Biochem</i>. 1987; 56:727-77. http://www.ncbi.nlm.nih.gov/pubmed/2441659?dopt=AbstractPlus</p><p>1466. Grob JJ, Collet AM, Munoz MH et al. Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. <i>Lancet</i>. 1988; 1:878-9. http://www.ncbi.nlm.nih.gov/pubmed/2895379?dopt=AbstractPlus</p><p>1467. Greenway HT, Cornell RC, Tanner DJ et al. Treatment of basal cell carcinoma with intralesional interferon. <i>J Am Acad Dermatol</i>. 1986; 15:437-43. http://www.ncbi.nlm.nih.gov/pubmed/3760271?dopt=AbstractPlus</p><p>1468. Edwards L, Tucker SB, Perednia D et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. <i>Arch Dermatol</i>. 1990; 126:1029-1032. http://www.ncbi.nlm.nih.gov/pubmed/2383027?dopt=AbstractPlus</p><p>1469. Greenway HT, Cornell RC. Interferon: coming of age. <i>Arch Dermatol</i>. 1990; 126:1080-2. http://www.ncbi.nlm.nih.gov/pubmed/2200348?dopt=AbstractPlus</p><p>1470. Cornell RC, Greenway HT, Tucker SB et al. Intralesional interferon therapy for basal cell carcinoma. <i>J Am Acad Dermatol</i>. 1990.</p><p>1479. American Medical Association Diagnostic and Therapeutic Technology Assessment (DATTA) panel. Alpha-interferon and chronic myelogenous leukemia. <i>JAMA</i>. 1990; 264:2137- 40. http://www.ncbi.nlm.nih.gov/pubmed/2214085?dopt=AbstractPlus</p><p>1530. Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. <i>J Clin Oncol</i>. 1993; 11:1969-77. http://www.ncbi.nlm.nih.gov/pubmed/8410122?dopt=AbstractPlus</p><p>1531. Dorval T, Negrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. <i>Cancer</i>. 1999; 85:1060-6. http://www.ncbi.nlm.nih.gov/pubmed/10091789?dopt=AbstractPlus</p><p>1532. Marincola FM, White DE, Wise AP et al. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. <i>J Clin Oncol</i>. 1995; 13:1110-22. http://www.ncbi.nlm.nih.gov/pubmed/7738617?dopt=AbstractPlus</p><p>1533. Renault PF, Hoofnagle JH. Side effects of alpha interferon. <i>Semin Liver Dis</i>. 1989; 9:273-7. http://www.ncbi.nlm.nih.gov/pubmed/2690351?dopt=AbstractPlus</p><p>1544. Genentech. Actimmune (interferon gamma-1b) prescribing information. South San Francisco, CA; 1991 Jan 2.</p><p>1546. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Drug Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD. From FDA website. Accessed 2012 Nov 9. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm</p><p>1549. Reviewers’ comments (personal observations).</p><p>1552. Glashan RW. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. <i>J Urol</i>. 1990; 144:658-61. http://www.ncbi.nlm.nih.gov/pubmed/2201795?dopt=AbstractPlus</p><p>1565. Lisker-Melman M, Di Bisceglie AM, Usala SJ et al. Autoimmune thyroid disease associated with recombinant human alpha interferon therapy in patients with chronic viral hepatitis. (unpublished observations)</p><p>1594. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. <i>Ann Intern Med</i>. 1991; 114:532-8. http://www.ncbi.nlm.nih.gov/pubmed/2001086?dopt=AbstractPlus</p><p>1619. Beutler E. Cladribine (2-chlorodeoxyadenosine). <i>Lancet</i>. 1992; 340:952-6. http://www.ncbi.nlm.nih.gov/pubmed/1357355?dopt=AbstractPlus</p><p>1620. Jaiyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. <i>Cancer</i>. 1993; 72:5-16. http://www.ncbi.nlm.nih.gov/pubmed/7685243?dopt=AbstractPlus</p><p>1621. Spielberger RT, Golomb HM. Hairy cell leukemia 1992. <i>Leukemia</i>. 1992; 6(Suppl 4):142-6. http://www.ncbi.nlm.nih.gov/pubmed/1279327?dopt=AbstractPlus</p><p>1622. Tallman MS, Hakimian D, Variakojis D et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. <i>Blood</i>. 1992; 80:2203-9. http://www.ncbi.nlm.nih.gov/pubmed/1358262?dopt=AbstractPlus</p><p>1623. Golomb HM, Ratain MJ, Mick R et al. The treatment of hairy cell leukemia: an update. <i>Leukemia</i>. 1992; 6(Suppl 2):24-7. http://www.ncbi.nlm.nih.gov/pubmed/1349662?dopt=AbstractPlus</p><p>1624. Baltz JK, Montello MJ. Cladribine for the treatment of hematologic malignancies. <i>Clin Pharm</i>. 1993; 12:805-13. http://www.ncbi.nlm.nih.gov/pubmed/7903917?dopt=AbstractPlus</p><p>1625. Anon. Drugs of choice for cancer. <i>Med Lett Treat Guid</i>. 2003; 1:41-52.</p><p>1627. Saven A, Piro LD. Treatment of hairy cell leukemia. <i>Blood</i>. 1992; 79:1111-20. http://www.ncbi.nlm.nih.gov/pubmed/1371410?dopt=AbstractPlus</p><p>1629. Anon. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia. <i>Med Lett Drugs Ther</i>. 1992; 34:89-90. http://www.ncbi.nlm.nih.gov/pubmed/1355592?dopt=AbstractPlus</p><p>1632. Bryson HM, Sorkin EM. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. <i>Drugs</i>. 1993; 46:872-94. http://www.ncbi.nlm.nih.gov/pubmed/7507037?dopt=AbstractPlus</p><p>1635. Dorr RT. Interferon-α in malignant and viral disease. A review. <i>Drugs</i>. 1993; 45:177-211. http://www.ncbi.nlm.nih.gov/pubmed/7681371?dopt=AbstractPlus</p><p>1636. Saven A, Piro LD, Carrera CJ et al. Hairy cell leukemia: new understanding of biology and treatment. In: Freireich EJ, Kantarjian H, eds. Leukemia—advances in research and treatment. Boston: Kluwer Academic Publishers; 1993:15-34.</p><p>1637. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. <i>N Engl J Med</i>. 1994; 330:691-7. http://www.ncbi.nlm.nih.gov/pubmed/7906385?dopt=AbstractPlus</p><p>1638. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. <i>N Engl J Med</i>. 1994; 330:820-5. http://www.ncbi.nlm.nih.gov/pubmed/8114834?dopt=AbstractPlus</p><p>1639. Wetzler M, Kantarjian H, Kurzrock R et al. Interferon-α therapy for chronic myelogenous leukemia. <i>Am J Med</i>. 1995; 99:402-11. http://www.ncbi.nlm.nih.gov/pubmed/7573097?dopt=AbstractPlus</p><p>1640. Kantarjian HM, Smith TL, O’Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. <i>Ann Intern Med</i>. 1995; 122:254-61. http://www.ncbi.nlm.nih.gov/pubmed/7825760?dopt=AbstractPlus</p><p>1641. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. <i>Blood</i>. 1994; 84:4064-77. http://www.ncbi.nlm.nih.gov/pubmed/7994025?dopt=AbstractPlus</p><p>1642. Kantarjian HM, Talpaz M. Interferon-α therapy in chronic myelogenous leukemia: questions related to the German randomized trial. <i>Blood</i>. 1995; 85:2998-9. http://www.ncbi.nlm.nih.gov/pubmed/7742562?dopt=AbstractPlus</p><p>1643. Tura S, Baccarani M. α-Interferon in the treatment of chronic myeloid leukemia. <i>Blood</i>. 1995; 85:2999-3000. http://www.ncbi.nlm.nih.gov/pubmed/7742563?dopt=AbstractPlus</p><p>1644. Hehlmann R, Heimpel H, Hasford J. Randomized comparison of interferon-α, hydroxyurea, and busulfan and in chronic myelogenous leukemia: response to Kantarjian and Talpaz and to Tura and Baccarani. <i>Blood</i>. 1995; 85:3000-2.</p><p>1647. Northfelt DW. Treatment of Kaposi’s sarcoma: current guidelines and future perspectives. <i>Drugs</i>. 1994; 48:569-82. http://www.ncbi.nlm.nih.gov/pubmed/7528130?dopt=AbstractPlus</p><p>1648. Krown SE. Interferon and other biologic agents for the treatment of Kaposi’s sarcoma. <i>Hematol Oncol Clin N Am</i>. 1991; 5:311-22.</p><p>1652. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. <i>J Clin Oncol</i>. 1996; 14:7-17. http://www.ncbi.nlm.nih.gov/pubmed/8558223?dopt=AbstractPlus</p><p>1694. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. <i>N Engl J Med</i>. 1996; 335:865-75. http://www.ncbi.nlm.nih.gov/pubmed/8778606?dopt=AbstractPlus</p><p>1697. Vogelzang NJ, Stadler WM. Kidney cancer. <i>Lancet</i>. 1998; 352:1691-6. http://www.ncbi.nlm.nih.gov/pubmed/9853456?dopt=AbstractPlus</p><p>1700. Minasian LM, Motzer RJ, Gluck L et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. <i>J Clin Oncol</i>. 1993; 11:1368-75. http://www.ncbi.nlm.nih.gov/pubmed/8315435?dopt=AbstractPlus</p><p>1732. Neidhart JA, Anderson SA, Harris JE et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. <i>J Clin Oncol</i>. 1991; 9:832-6. http://www.ncbi.nlm.nih.gov/pubmed/2016626?dopt=AbstractPlus</p><p>1747. Prometheus. Proleukin<sup></sup> (aldesleukin) for injection prescribing information. San Diego, CA; 2012 Jul.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>